US20080305160A1 - Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule Form - Google Patents
Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule Form Download PDFInfo
- Publication number
- US20080305160A1 US20080305160A1 US11/791,466 US79146605A US2008305160A1 US 20080305160 A1 US20080305160 A1 US 20080305160A1 US 79146605 A US79146605 A US 79146605A US 2008305160 A1 US2008305160 A1 US 2008305160A1
- Authority
- US
- United States
- Prior art keywords
- active principle
- microcapsules
- medicament
- release
- modified release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 90
- 239000003094 microcapsule Substances 0.000 claims abstract description 171
- 230000007246 mechanism Effects 0.000 claims abstract description 12
- -1 alkaline earth metal salts Chemical class 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 65
- 239000011248 coating agent Substances 0.000 claims description 51
- 238000000576 coating method Methods 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 42
- 230000008961 swelling Effects 0.000 claims description 41
- 239000011859 microparticle Substances 0.000 claims description 40
- 229960004150 aciclovir Drugs 0.000 claims description 31
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 31
- 238000000338 in vitro Methods 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 29
- 238000004090 dissolution Methods 0.000 claims description 28
- 230000007935 neutral effect Effects 0.000 claims description 26
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims description 16
- 210000002784 stomach Anatomy 0.000 claims description 15
- 229960004195 carvedilol Drugs 0.000 claims description 13
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 13
- 229960000913 crospovidone Drugs 0.000 claims description 13
- 238000007922 dissolution test Methods 0.000 claims description 13
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 13
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 235000010980 cellulose Nutrition 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 9
- 230000007717 exclusion Effects 0.000 claims description 9
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 9
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 9
- 229960002256 spironolactone Drugs 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 229960000564 nitrofurantoin Drugs 0.000 claims description 8
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 8
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 8
- 235000019482 Palm oil Nutrition 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000002540 palm oil Substances 0.000 claims description 7
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 229940049654 glyceryl behenate Drugs 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 241001440269 Cutina Species 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 229960000623 carbamazepine Drugs 0.000 claims description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 150000005690 diesters Chemical class 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 229960004503 metoclopramide Drugs 0.000 claims description 4
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000002960 penicillins Chemical class 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- 229960002292 piperacillin Drugs 0.000 claims description 4
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 4
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
- 229960004659 ticarcillin Drugs 0.000 claims description 4
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 4
- 150000005691 triesters Chemical class 0.000 claims description 4
- 229940113164 trimyristin Drugs 0.000 claims description 4
- 229960001947 tripalmitin Drugs 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 230000000378 dietary effect Effects 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003174 lansoprazole Drugs 0.000 claims description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 3
- 239000006194 liquid suspension Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 239000012165 plant wax Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 2
- KMEGBUCIGMEPME-LQYKFRDPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylic acid Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 KMEGBUCIGMEPME-LQYKFRDPSA-N 0.000 claims description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims description 2
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Chemical class CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- MHQJUHSHQGQVTM-VHEBQXMUSA-N (e)-4-octadecoxy-4-oxobut-2-enoic acid Chemical class CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C(O)=O MHQJUHSHQGQVTM-VHEBQXMUSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims description 2
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 claims description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Chemical class CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Chemical class CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 108010065839 Capreomycin Proteins 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 claims description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 claims description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 2
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 239000004169 Hydrogenated Poly-1-Decene Substances 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Chemical class 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Chemical class CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 claims description 2
- 229930195708 Penicillin V Natural products 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- 206010041277 Sodium retention Diseases 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 2
- 208000001871 Tachycardia Diseases 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- 208000012886 Vertigo Diseases 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 229960004538 alprazolam Drugs 0.000 claims description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
- 229940063655 aluminum stearate Drugs 0.000 claims description 2
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003556 anti-epileptic effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002785 anti-thrombosis Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 229940125684 antimigraine agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 229960004676 antithrombotic agent Drugs 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 239000003699 antiulcer agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 229940005530 anxiolytics Drugs 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 claims description 2
- 229960002699 bacampicillin Drugs 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 229960004602 capreomycin Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- 229960000954 carbenicillin indanyl sodium Drugs 0.000 claims description 2
- QFWPXOXWAUAYAB-XZVIDJSISA-M carindacillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 QFWPXOXWAUAYAB-XZVIDJSISA-M 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 229960004841 cefadroxil Drugs 0.000 claims description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 2
- 229960003012 cefamandole Drugs 0.000 claims description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 2
- 229960004350 cefapirin Drugs 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960002100 cefepime Drugs 0.000 claims description 2
- 229960002129 cefixime Drugs 0.000 claims description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960004292 ceforanide Drugs 0.000 claims description 2
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 claims description 2
- 229960004261 cefotaxime Drugs 0.000 claims description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 2
- 229960005495 cefotetan Drugs 0.000 claims description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 2
- 229960002682 cefoxitin Drugs 0.000 claims description 2
- 229960005090 cefpodoxime Drugs 0.000 claims description 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 2
- 229960004086 ceftibuten Drugs 0.000 claims description 2
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 claims description 2
- 229960001991 ceftizoxime Drugs 0.000 claims description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960004287 clofazimine Drugs 0.000 claims description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 2
- 229960003326 cloxacillin Drugs 0.000 claims description 2
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 2
- 229940124558 contraceptive agent Drugs 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 229960003077 cycloserine Drugs 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001585 dicloxacillin Drugs 0.000 claims description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
- 229960004166 diltiazem Drugs 0.000 claims description 2
- 229960004100 dirithromycin Drugs 0.000 claims description 2
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229950000206 estolate Drugs 0.000 claims description 2
- 229960004766 estradiol valerate Drugs 0.000 claims description 2
- 229960000285 ethambutol Drugs 0.000 claims description 2
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002001 ethionamide Drugs 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001596 famotidine Drugs 0.000 claims description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001419 fenoprofen Drugs 0.000 claims description 2
- 229960002679 fentiazac Drugs 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 229960002464 fluoxetine Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000308 fosfomycin Drugs 0.000 claims description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001731 gluceptate Drugs 0.000 claims description 2
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 229940116364 hard fat Drugs 0.000 claims description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229960002182 imipenem Drugs 0.000 claims description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960003350 isoniazid Drugs 0.000 claims description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Chemical class CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 229940099584 lactobionate Drugs 0.000 claims description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960002422 lomefloxacin Drugs 0.000 claims description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001977 loracarbef Drugs 0.000 claims description 2
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 229960004011 methenamine Drugs 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 229960002237 metoprolol Drugs 0.000 claims description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- 229960000210 nalidixic acid Drugs 0.000 claims description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229960000381 omeprazole Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 229940056367 penicillin v Drugs 0.000 claims description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004448 pentamidine Drugs 0.000 claims description 2
- 229960005301 pentazocine Drugs 0.000 claims description 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 2
- 125000005498 phthalate group Chemical class 0.000 claims description 2
- 239000010773 plant oil Substances 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 208000007232 portal hypertension Diseases 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003368 psychostimulant agent Substances 0.000 claims description 2
- 229960001404 quinidine Drugs 0.000 claims description 2
- 229960000620 ranitidine Drugs 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 2
- 229960002052 salbutamol Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229940023144 sodium glycolate Drugs 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940114926 stearate Drugs 0.000 claims description 2
- 239000008117 stearic acid Chemical class 0.000 claims description 2
- 150000003900 succinic acid esters Chemical class 0.000 claims description 2
- 229960002076 sulfacytine Drugs 0.000 claims description 2
- SIBQAECNSSQUOD-UHFFFAOYSA-N sulfacytine Chemical compound O=C1N(CC)C=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 SIBQAECNSSQUOD-UHFFFAOYSA-N 0.000 claims description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004306 sulfadiazine Drugs 0.000 claims description 2
- 229960002135 sulfadimidine Drugs 0.000 claims description 2
- 229960000654 sulfafurazole Drugs 0.000 claims description 2
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002597 sulfamerazine Drugs 0.000 claims description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960002211 sulfapyridine Drugs 0.000 claims description 2
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims description 2
- 229960003865 tazobactam Drugs 0.000 claims description 2
- 229960000351 terfenadine Drugs 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 229960001082 trimethoprim Drugs 0.000 claims description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001099 trimetrexate Drugs 0.000 claims description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 2
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical group BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 229960001722 verapamil Drugs 0.000 claims description 2
- 231100000889 vertigo Toxicity 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000004207 white and yellow bees wax Substances 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- 229960002555 zidovudine Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 230000001419 dependent effect Effects 0.000 abstract description 10
- 230000036962 time dependent Effects 0.000 abstract description 9
- 230000009977 dual effect Effects 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 230000000069 prophylactic effect Effects 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 21
- 230000003111 delayed effect Effects 0.000 description 20
- 238000013270 controlled release Methods 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000004005 microsphere Substances 0.000 description 15
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 13
- 239000007921 spray Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 11
- 239000007836 KH2PO4 Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 11
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 230000001960 triggered effect Effects 0.000 description 9
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 8
- 229960004920 amoxicillin trihydrate Drugs 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 229920006310 Asahi-Kasei Polymers 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 229940069328 povidone Drugs 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 5
- 229920003141 Eudragit® S 100 Polymers 0.000 description 4
- 229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 4
- 238000005563 spheronization Methods 0.000 description 4
- 229920003139 Eudragit® L 100 Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- LHNYXTULDSJZRB-UHFFFAOYSA-N 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2.COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 LHNYXTULDSJZRB-UHFFFAOYSA-N 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- 229920003136 Eudragit® L polymer Polymers 0.000 description 2
- 229920003085 Kollidon® CL Polymers 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000370 carvedilol phosphate Drugs 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 230000003280 chronobiological effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the field of the present invention is that of micro-particulate systems for the delayed and controlled release of active principle(s) AP(s), for oral administration.
- the APs envisioned in the present invention are in particular those which have an absorption essentially limited to the upper parts of the gastrointestinal tract, located upstream of the colon (of the ileocecal junction), and which represent a large majority of pharmaceutical active principles.
- the active principles most especially targeted are “low-solubility” active principles.
- the invention relates to a microparticulate galenic form for delayed and controlled release, for which the controlled release phase is triggered in a definite manner by means of a double mechanism: “time-dependent” release triggered after a certain period of time spent in the stomach and “pH-dependent” release triggered by a change in pH when the particles enter the small intestine and which begins without any lag time.
- the microparticles of the present invention are microcapsules containing at least one active principle (AP)— with the exclusion of carvedilol—, having a particle size of less than 2000 microns, individually coated with a coating film for the delayed and controlled release of the AP.
- AP active principle
- the invention also relates to the microcapsules for the modified release of at least one active principle, taken as such.
- the expression “low-solubility active principle” denotes any active principle, with the exclusion of carvedilol, which has a solubility of less than or equal to approximately 50 g/l, preferably less than or equal to approximately 20 g/l, even more preferably less than or equal to approximately 5 g/l and, for example, less than or equal to 0.1 g/l.
- microcapsules denotes microparticles of active principle, coated with at least one coating for the modified release of at least one active principle (in particular, a low-solubility active principle).
- carvedilol denotes carvedilol per se, one or more pharmaceutically acceptable salts of carvedilol or one or more pharmaceutically acceptable esters of carvedilol, or any mixture of these active agents.
- modified release denotes, without distinction, a prolonged release of the active principle(s), beginning as soon as the microcapsules are brought into contact with the dissolving medium and extending from 0.5 h to 24 h, preferably 1 h to 10 h, or a release of the active principle(s) that begins only after a predetermined period (lag time) ranging, for example, from 0.5 to several hours, with a release time for 50% of the active principle(s) which is typically several hours and which can extend from 0.5 to 30 hours, for example.
- lag time ranging, for example, from 0.5 to several hours
- a release time for 50% of the active principle(s) which is typically several hours and which can extend from 0.5 to 30 hours, for example.
- immediate release denotes a release of the active principle(s) that begins as soon as the galenic form is brought into contact with the dissolving medium (in vivo or in vitro) with a release time for 80% of the active principle(s) which is less than or equal to 1 h, and for example less than or equal to 20 min.
- Systems for the delayed and controlled release of active principle(s) are particularly useful when it is desirable, for chronobiological reasons, for the active principle(s) to be “bioabsorbed” at a specific time of the day in order to be in phase with the circadian cycle. It may, for example, be advantageous for the active principle(s) to be bioabsorbed very early in the morning in order to ensure therapeutic cover when the patient wakes up, without however restricting the latter to an early wake-up. To do this, the galenic system ingested by the patient, for example in the evening after the evening meal, should allow a delayed release of the active principle(s).
- Another desired property for systems for the delayed and controlled release of active principle(s) is an improvement in the plasma concentration profile obtained after administration.
- the intended aim is to obtain a plasma profile which is maintained above the effective therapeutic concentration, for as long as possible, in order to maximize the duration of action of the active principle(s), and therefore its (their) therapeutic effectiveness.
- This aim comes up against the residence time of the active principle(s) in the blood compartment, which is most commonly much less than one day.
- pH-dependent delayed-release forms are thus known, which are obtained by coating the active principle(s) by means of a layer of enteric polymer, for example of copolymer of methacrylic acid and methacrylic acid methyl ester: EUDRAGIT® L.
- enteric polymer for example of copolymer of methacrylic acid and methacrylic acid methyl ester: EUDRAGIT® L.
- This type of enteric coating is known to provide a reduced permeability under the acidic pH conditions of the stomach and to dissolve when the pH goes back up to a value close to that which occurs in the small intestine, thus releasing the active principle(s).
- intra- and inter-individual variability in gastric pH conditions and in the duration of gastric emptying do not make it possible to definitely ensure the release of the active principle(s) after a given period of time.
- Delayed-release systems that are purely dependent on the time after ingestion (“time-dependent”), i.e. systems for which the release of the active principle(s) is triggered after a given period of time spent in the gastrointestinal tract, are, moreover, known and are not satisfactory either.
- time-dependent i.e. systems for which the release of the active principle(s) is triggered after a given period of time spent in the gastrointestinal tract.
- the release of the active principle(s) can take place after the latter has passed in front of its absorption window, which is located, for most active principles, in the upper parts of the gastrointestinal tract.
- the bioabsorption can thus be very low, or even zero.
- microcapsules have an in vitro dissolution behavior such that, at constant pH 1.4, a lag phase of between 1 and 5 hours is observed, followed by an active principle release phase, and such that the change from pH 1.4 to pH 6.8 brings about release of the active principle without any lag time in vitro.
- the multimicroparticulate galenic system according to PCT patent application WO-A-03/030878 also makes it possible to adjust the lag time preceding the release of the AP in the stomach by taking into consideration the physiological conditions of the gastrointestinal tract in humans.
- This advantageous method is thus a means of minimizing the interindividual variability of absorption of the AP.
- the residence time, in the stomach, of a preparation is very variable, of the order of from 0.5 to 10 hours.
- the abovementioned system makes it possible to release the active principle in the stomach after a given constant lag time within this range of 0.5-10 hours, such that, from one individual to the other, or even from one day to the other for the same individual, the medicament action time is the same.
- microparticulate oral galenic form for the delayed and controlled release of AP according to WO-A-03/030878, simultaneously has the following properties:
- a microencapsulated active principle in order to be released, a microencapsulated active principle must first of all be reached by the fluids of the gastrointestinal tract, which, in order to do this, must cross the coating film of the microcapsules. The microencapsulated active principle can then dissolve in these fluids. The active principle solution thus obtained can subsequently diffuse out of the microcapsules through the coating film(s) of said microcapsules.
- the coating film of the microcapsules in order to obtain a lag time of between 0.5 and 7 h, for example of 2-3 h, it is important for the coating film of the microcapsules to have a sufficient thickness (in ⁇ m) and/or to represent a sufficient degree of film-coating DF (in % by weight) so that the entry time of a liquid such as water or a gastrointestinal tract fluid into the microcapsule allows delayed release of the active principle.
- This minimum thickness can, for example, correspond to a DF of 10-40%, for example.
- the “time-dependent” release, just like the “pH-dependent” release, of the active principle is still as effective, but becomes slower, which can be detrimental to the bioavailability.
- One of the essential objectives of the invention is to provide an oral medicament that is improved in relation to that described in WO-A-03/030878, specifically a multimicrocapsule oral medicament for the modified release of active principle(s), in particular of low-solubility active principle(s), which guarantees correct functioning of the dual “time-dependent” and “pH-dependent” trigger mechanism for the release of the active principle, in particular for low-solubility active principles.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s) that makes it possible to judiciously adjust the release kinetics of the active principle all along its window of absorption in the gastrointestinal tract so that the plasma concentration profile is maintained above the effective therapeutic concentration for as long as possible, and in particular for a period of time greater than that of the immediate-release form.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which provides a suitable solution to the problem of chronotherapy and to the difficulties of compliance relating thereto.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which makes it possible to readily combine at least two active principles in the same pharmaceutical form.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which, contrary to the compact monolithic forms, offers a reduced interindividual variability.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which allows an increase in the gastrointestinal transit time and absorption of the active principle in the upper parts of the gastrointestinal tract.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), it being possible for this medicament to exist in a presentation form that can be administered once a day, which would represent significant progress, in particular in terms of patient compliance.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which can be produced according to a sound industrial process.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which is easy to prepare, for example by deposition of a coating by spraying onto microparticles containing low-solubility active principle.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which is capable of having high contents of active principle(s), for example up to 60% by weight of the microcapsules.
- Another essential objective of the invention is to provide an oral medication for the modified release of active principle(s), which contains a plurality of microcapsules and has a dose-independent in vitro active principle release profile.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which makes it possible to obtain a plasma concentration (C24h) of active principle(s) 24 h after oral administration which is as high as possible.
- Another essential objective of the invention is to provide microcapsules for the modified release of active principles, which can be used in particular for preparing a medicament as defined by the specifications stated in the above objectives.
- an oral medicament comprising a plurality of microcapsules for the modified release of active principle(s), at least some of said microcapsules consisting individually of a microparticle comprising at least one active principle, in particular at least one low-solubility active principle (with the exclusion of carvedilol), coated with at least one coating for the modified release of the active principle(s), said release being controlled by two distinct trigger mechanisms, one being based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of time spent in the stomach,
- said coating also conferring on the microcapsules an in vitro dissolution behavior such that:
- the in vitro dissolution behavior is determined according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm.
- the medicament according to the invention overcomes the abovementioned technical problem, i.e. the release of low-solubility active principle(s) AP(s) according to a dual “time-dependent” and “pH-dependent” trigger mechanism, thereby accelerating the release of the active principle, in particular compared with the release times obtained by the invention according to WO-A-03/030878.
- the medicament according to the invention ultimately improves the prophylactic and therapeutic efficacy of such low-solubility active principles.
- the medicament according to the invention is also advantageous in that it offers in particular the following advantages:
- plasma concentration of active principle(s) 24 h after oral administration close to or greater than that which would be obtained with an immediate-release form taken in several doses.
- the swelling agent comprises at least one hydrophilic pharmaceutically acceptable compound which exhibits a degree of swelling in water at 25° C. of greater than or equal to 10% by weight, preferably greater than or equal to 15% by weight, and even more preferably greater than or equal to 20%.
- the size (Td) of the particles of swelling agent is advantageously selected within the average diameter ranges, in ⁇ m, of between 5 and 200 ⁇ m, and preferably between 10 and 50 ⁇ m.
- concentration (Cd) of swelling agent is selected within the following ranges of % by weight relative to the total mass of the microcapsules:
- the swelling agent is chosen from the group of following products:
- the swelling agent is chosen from the subgroup of following products:
- the medicament comprises at least one wetting agent, preferably chosen from the group of following products:
- the medicament according to the invention is multimicrocapsular, i.e. it comprises, inter alia, microcapsules consisting of microparticles of coated or film-coated active principle.
- microparticles of active principle may be, for example, crude (pure) active principle in pulverulent form, matrix granules of active principle with various other ingredients, or alternatively neutral microspheres, for example made of cellulose or of sugar, coated with at least one layer comprising active principle.
- modified-release microcapsules of active principle can be compared to microunits containing at least one active principle and forming at least some of the constitutive elements of the medicament according to the invention.
- Each microcapsule can contain one or more active principles that are identical to or different than one another.
- the medicament according to the invention can comprise microunits of active principle other than microcapsules. They could, for example, be microcapsules for the immediate release of active principle(s). The latter may, for example, be uncoated microparticles of active principle(s) of the same type as those that can be used in the preparation of the microcapsules according to the invention.
- Each microparticle can comprise one or more active principles that are identical to or different than one another.
- the collection of microunits (microparticles and/or microcapsules) constituting the medicament according to the invention can be made up of various populations of microunits, these populations differing from one another at least by virtue of the nature of the active principle(s) contained in these microunits and/or by virtue of the composition of the coating.
- microcapsules used in the medicament according to the invention two preferred embodiments of the structure of the microcapsules are described in detail hereinafter, in a nonlimiting capacity.
- microcapsules for the modified release of active principle(s) each comprise:
- the microparticle of active principle(s) is a granule comprising the active principle(s) and one or more pharmaceutically acceptable excipients.
- the swelling agent(s) is (are) contained in the microparticle (e.g. granule).
- wetting agent(s) it (they) is (are) preferably contained in the microparticle (e.g. granule) and/or in the coating for the modified release of the active principle(s).
- microcapsules for the modified release of active principle(s) each comprise:
- the neutral core contains sucrose and/or dextrose and/or lactose.
- the neutral core is a cellulose microsphere.
- the neutral core has an average diameter of between 1 and 800 ⁇ m, and preferably between 20 and 500 ⁇ m.
- the active layer can optionally comprise, in addition to the active principle(s), one or more pharmaceutically acceptable excipients.
- the swelling agent(s) is (are) contained in the active layer.
- this active layer comprises active principle, at least one swelling agent, at least one binder and at least one surfactant.
- wetting agent(s) it (they) is (are) preferably contained in the active layer.
- the present invention also consists in selecting microcapsules having the following specificities:
- the composite material AB of the coating for the modified release of the low-solubility active principle is such that:
- the hydrophilic polymer A is chosen from:
- the polymers A that are even more preferred are copolymers of (meth)acrylic acid and of (meth)acrylic acid alkyl (e.g. C 1 -C 6 alkyl) esters.
- These copolymers are, for example, of the type such as those sold by the company Röhm Pharma Polymers under the registered trademarks EUDPAGIT®, of the series L and S (such as, for example, EUDRAGIT® L100, S100, L30 D-55 and L100-55).
- These copolymers are anionic enteric copolymers that are soluble in an aqueous medium at pHs above those encountered in the stomach.
- the compound B is chosen from the group of following products:
- the compound B is chosen from the group of following products: hydrogenated cottonseed oil, hydrogenated soya bean oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin, yellow wax, hard fat or fat that can be used as bases for suppositories, anhydrous dairy fats, lanolin, glyceryl palmitostearate, glyceryl stearate, lauryl macrogolglycerides, cetyl alcohol, polyglyceryl diisostearate, diethylene glycol monostearate, ethylene glycol monostearate, Omega 3 and any mixture thereof,
- compound B is preferably chosen:
- the coating for the modified release of the low-solubility active principle is free of talc.
- the active principle is deposited onto the core by techniques known to those skilled in the art, for example the fluidized air bed spray coating technique, wet granulation, compacting, extrusion-spheronization, etc.
- the coating of the microcapsules can comprise, in addition to the essential constituents A and B, other conventional ingredients known to those skilled in the art, such as, in particular:
- the coating of the microcapsules for the modified release of active principle comprises a single composite AB coating film.
- the monolayer of coating can represent, for example, at most 40%, preferably at most 30% by weight of the microcapsules.
- Such a limited degree of coating makes it possible to prepare galenic units that each contain a high dose of active principle, without exceeding a size that would be completely unacceptable with regard to swallowing. The compliance with and therefore the success of the treatment can only be improved by this.
- the mechanism for triggering the release of the low-solubility active principle without any variation in pH, after a predetermined residence time in the stomach, results in particular from the control of the rate of hydration of the microcapsules and/or of the dissolution of one or more components of the microcapsules.
- the hydration of the microcapsule can be controlled:
- One of the determining advantages of the multimicrocapsule galenic system for the delayed and controlled release of active principle(s), for example of low-solubility principle(s), according to the invention, is to involve, in vivo, two factors that trigger the release of the active principle(s), for example of the low-solubility principle(s), in the gastrointestinal tract, i.e.:
- any active principle e.g. low-solubility active principle
- the window of absorption of which is limited to the upper parts of the gastrointestinal tract it is particularly advantageous for the form for the delayed and then prolonged and controlled release to be made up of a plurality of microcapsules.
- the dose of active principle (e.g. low-solubility active principle) to be administered is divided up between a large number of microcapsules (typically 5000-50 000) and as a result provides the following intrinsic advantages:
- the multimicrocapsule galenic system according to the invention makes it possible to ensure, in a reliable manner, a delayed and controlled release of the low-solubility active principle in the gastrointestinal tract by virtue of two triggers, and to thus escape the inter- and intraindividual variability of the conditions of gastric emptying, while at the same time being economically viable and easy to ingest (optimized compliance).
- Another subject of the invention relates to an oral medicament comprising a plurality of microcapsules for the modified release of active principle(s), at least some of said microcapsules consisting individually of a microparticle comprising at least one active principle, in particular at least one low-solubility active principle (with the exclusion of carvedilol), coated with at least one coating for the modified release of the active principle(s), said release being controlled by two distinct trigger mechanisms, one based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of time spent in the stomach,
- helpers suitable for increasing the permeability of the coating, so as to reduce the release time, in particular for low-solubility active principles.
- the release helper consists of at least one swelling agent, as defined above.
- the medicament according to this other subject of the invention is also remarkable in that the coating of the microcapsules included in this medicament confers on said microcapsules an in vitro dissolution behavior (produced according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm),
- the medicament according to the invention consists of a plurality of microunits makes it possible to obtain another essential characteristic of the invention, according to which the medicament comprises a mixture of various populations of microunits containing active principle(s) (with the exclusion of carvedilol), these populations differing from one another by virtue of their respective in vitro dissolution profiles, for at least one pH value of between 1.4 and 7.4.
- This essential characteristic makes it possible to obtain an increase in the bioabsorption time of the active principle(s) and therefore in the time during which the plasma concentration is greater than the minimum effective concentration of this active principle.
- the mixture of various populations of microunits brings about a preferential release of the active principle(s) at different sites of the gastrointestinal tract, over the entire extent of the window of bioabsorption of the active principle(s) in the gastrointestinal tract.
- the medicament according to the invention is characterized in that the microunits are microcapsules for the modified release of active principle(s) and, optionally, microunits for the immediate release of active principle(s).
- the populations of microcapsules for the modified release of active principle(s) differ by virtue of their respective trigger pHs.
- the populations of microcapsules for the modified release of active principle(s) can differ not only by virtue of their respective trigger pHs, but also by virtue of their respective trigger times, or even by virtue of their respective trigger pHs and times.
- the medicament comprises:
- said respective trigger pHs are between 5 and 7.
- the medicament comprises:
- the release profile (measured in an in vitro release test as defined above) of the modified-release microcapsules used in the abovementioned mixtures of various populations of microunits may, for example, be as indicated hereinafter:
- the medicament according to the invention comprises at least one population of microunits containing immediate-release active principle(s)
- this population can advantageously be defined by its behavior in an in vitro dissolution test, said behavior being such that at least 80% of the active principle(s) is released in 1 hour at any pH between 1.4 and 7.4.
- the proportion of low-solubility active principle(s) in the microunits containing active principle(s) is between 5 and 80, preferably between 10 and 70, and even more preferably between 15 and 60.
- the microunits containing immediate-release active principle(s) are uncoated microparticles.
- the medicament according to the invention is particularly advantageous in that it can be in the form of a single daily oral dose comprising:
- This plurality of microcapsules constitutes a galenic form that is entirely well tolerated by the mammalian organism.
- microcapsules are all the more advantageous since they are manufactured simply and economically according to techniques well known to those skilled in the art, for example the fluidized air bed spray coating technique, wet granulation, compacting, extrusion-spheronization, etc.
- the medicament in multimicroparticulate oral galenic forms according to the invention can be a tablet, advantageously an orodispersible tablet, a powder, a liquid suspension or a gelatin capsule containing microcapsules.
- this medicament can be in the form of a sachet of microcapsule powder, of a liquid suspension of microcapsules, of a tablet obtained from microcapsules or a gelatin capsule containing microcapsules.
- These tablets, these gelatin capsules, these powders and these suspensions can consist of mixtures of the various populations of microunits, and in particular of microcapsules of active principle(s) according to the invention, preferably combining therewith microunits or microparticles for the immediate release of low-solubility active principle (for example granules).
- the invention is directed toward the use of the microcapsules for the modified release of active principle(s) as defined above and, optionally, of microunits containing immediate-release active principle(s), for the preparation of pharmaceutical or dietetic, microparticulate oral galenic forms, preferably in the form of advantageously orodispersible tablets, of powders or of gelatin capsules.
- the invention relates to the microcapsules as defined above, taken as such.
- the active principle(s) can be chosen from at least one of the following major varieties of active substances, e.g.: antiulcer agents, antidiabetic agents, anticoagulants, antithrombotics, blood-lipid-lowering agents, antiarrhythmics, vasodilators, anti-angina agents, antihypertensives, vasoprotectors, fertility promoters, inhibitors and inducers of uterine labor, contraceptives, antibiotics, antifungals, antivirals, anticancer agents, anti-inflammatories, analgesics, antiepileptics, antiparkinsonian agents, neuroleptics, hypnotics, anxiolytics, psychostimulants, antimigraine agents, antidepressants, antitussives, antihistamines or anti-allergic agents, agents for combating congestive heart failure, angina pectoris, left ventricular hypertrophy, cardiac arrhythmias, myocardial infarction, reflex tachycardia,
- active principles that may be contained in the medicament according to the invention, mention may be made of those chosen from the group of following compounds: acetylsalicylic acid, carbamazepine pentoxifylline, prazosine, acyclovir, nifedipine, diltiazem, naproxen, ibuprofen, flurbiprofen, ketoprofen, fenoprofen, indomethacin, diclofenac, fentiazac, estradiol valerate, metoprolol, sulpiride, captopril, cimetidine, zidovudine, nicardipine, terfenadine, atenolol, salbutamol, carbamazepine, ranitidine, enalapril, simvastatin, fluoxetine, alprazolam, famotidine, ganciclovir, famciclovir, spirono
- the active principle(s) is (are) one of the low-solubility active principle(s), for example chosen from the active principles as mentioned above (taken by themselves or as a mixture with one another).
- the active principles to which the present invention also relates may also be nutritional and/or dietetic supplements or mixtures thereof, for instance vitamins, amino acids, antioxidants or trace elements, or mixtures thereof.
- the invention is also directed toward a method of therapeutic treatment, characterized in that it consists of an oral administration, according to a given dosage, of the medicament according to the invention as defined above.
- FIG. 1 in vitro release profiles of the microcapsules prepared according to comparative example 1.
- FIG. 2 in vitro release profiles of the microcapsules prepared according to comparative example 2.
- FIG. 3 in vitro release profiles of the microcapsules prepared according to comparative example 3.
- FIG. 4 in vitro release profiles of the microcapsules prepared according to comparative example 4.
- FIG. 5 in vitro release profiles of the microcapsules prepared according to example 5 and comparison with the release profiles of the microcapsules prepared according to comparative example 1.
- FIG. 6 in vitro release profiles of the microcapsules prepared according to example 6 and comparison with the release profiles of the microcapsules prepared according to comparative example 2.
- FIG. 7 in vitro release profiles of the microcapsules prepared according to example 7 and comparison with the release profiles of the microcapsules prepared according to comparative example 3.
- FIG. 8 release profiles of the microcapsules prepared according to examples 8, 9 and 10 at pH 1.4.
- FIG. 9 release profiles of the microcapsules prepared according to examples 8, 9 and 10, measured for 2 h at pH 1.4 and then at pH 6.8.
- FIG. 10 release profiles of the microcapsules prepared according to examples 10, 11, 12 and 13 at pH 1.4.
- FIG. 11 release profiles of the microcapsules prepared according to example 14.
- FIG. 12 release profiles of the microcapsules prepared according to example 15.
- FIG. 13 release profiles of the microcapsules prepared according to example 16.
- FIG. 14 release profiles of the microcapsules prepared according to example 17.
- Comparative example 1 spironolactone
- comparative example 2 amoxicillin trihydrate
- comparative example 3 nitrogenantoin
- comparative example 4 carvedilol
- the microcapsules of comparative examples 1 to 4 do not comprise any swelling agent.
- Examples 8, 9 and 10 show the influence of the amount of swelling agent present in the formulas on the release kinetics at pH 1.4.
- Examples 11, 12 and 13 illustrate a nonexhaustive selection of the swelling agents that may be used in the formulas according to the invention.
- Example 14 illustrates the preparation of microcapsules, combining a wet granulation step and a fluidized air bed coating step.
- Example 15 illustrates the preparation of microcapsules, combining an extrusion/spheronization step and a fluidized air bed coating step.
- Example 16 illustrates the preparation of microcapsules, combining a compacting step and a fluidized air bed coating step.
- Example 17 illustrates the preparation of a medicament composed of the mixture of various types of microunits.
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- novel compositions according to the invention make it possible to accelerate the release profiles at pH 1.4 and at pH 6.8, while at the same time conserving the lag phase at pH 1.4.
- 1620 g of amoxicillin trihydrate and 180 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) are dispersed in 4200 g of purified water.
- the suspension is sprayed onto 200 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- novel compositions according to the invention make it possible to optimize the release profiles at pH 1.4, while at the same time maintaining a rapid release at pH 6.8 and while at the same time conserving a lag phase at pH 1.4.
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- novel compositions according to the invention make it possible to optimize the release profiles at pH 1.4, while at the same time maintaining a rapid release at pH 6.8 and while at the same time conserving a lag phase at pH 1.4.
- 1120 g of carvedilol phosphate and 280 g of Plasdone K29/32® (ISP) are dispersed in 1120 g of purified water.
- the suspension is sprayed onto 600 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the Pharmacopoeia, at 37° C. and with stirring at 100 rpm, in the following media:
- spironolactone 72 g of low molar mass hydroxypropylcellulose (Klucel® EF/Hercules), 72 g of PEG-40 hydrogenated castor oil (Cremophor RH 40/BASF) and 360 g of crospovidone (Kollidon CL/BASF) are dispersed in 1120 g of purified water.
- the suspension is sprayed onto 720 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- amoxicillin trihydrate 90 g of povidone (plasdone® K29/32 (ISP)) and 180 g of crospovidone (Polyplasdone®/ISP) are dispersed in 2100 g of isopropanol/water mixture (70/30 m/m). The solution is sprayed onto 100 g of neutral microspheres (Asahi-Kasei) in a Glatt® GPCG1 spray coater.
- ISP povidone
- crospovidone Polyplasdone®/ISP
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- nitrofurantoin 200 g of povidone (plasdone® K29/32/ISP), 50 g of PEG-40 hydrogenated castor oil (BASF) and 350 g of crospovidone (Polyplasdone®/ISP) are suspended in 2500 g of purified water.
- the solution is sprayed onto 1000 g of neutral microspheres (Asahi-Kasei) in a Glatt® GPCG1 spray coater.
- microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- acyclovir 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 75 g of crospovidone (Polyplasdone®/ISP are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG3 spray coater.
- Klucel® EF Hercules
- crospovidone Polyplasdone®/ISP
- acyclovir 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 150 g of crospovidone (Polyplasdone®/ISP are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG3 spray coater.
- Klucel® EF Hercules
- crospovidone Polyplasdone®/ISP
- microcapsules obtained at the end of the second step in comparative examples 8, 9 and 10 were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- acyclovir 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 150 g of sodium croscarmellose (Ac-Di-Sol®/FMC) are suspended in 1200 g of purified water.
- the solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG1 spray coater.
- acyclovir 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 150 g of hydroxypropylmethylcellulose (Pharmacoat 615 /Shin-Etsu) are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG1 spray coater.
- Klucel® EF Hercules
- Pharmacoat 615 /Shin-Etsu hydroxypropylmethylcellulose
- acyclovir 350 g of acyclovir, 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 100 g of high molar mass povidone (Kollidon® 90 (BASF)) are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG1 spray coater.
- Klucel® EF Hercules
- Kollidon® 90 BASF
- microcapsules obtained at the end of the second step in examples 10, 11, 12 and 13 were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, at pH 1.4.
- the dissolution profiles are presented in FIG. 10 .
- acyclovir 50 g of povidone (Plasdone®/ISP) and 250 g of crospovidone (Polyplasdone®/ISP) are dry-mixed beforehand in a laboratory granulator (Lodige) for 5 minutes. This pulverulent mixture is then granulated with water (200 g). The granules are dried at 40° C. in a ventilated oven, and then calibrated on a 500 ⁇ m screen. The 200-500 ⁇ m fraction is selected by screening.
- microcapsules obtained at the end of the second step of example 13 were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- the dissolution profiles are presented in FIG. 11 .
- 700 g of acyclovir, 50 g of povidone (Plasdone®/ISP) and 250 g of crospovidone (Kollidon® CL/BASF) are premixed with 150 g of water in a laboratory mixer (Kitchen-Aid) for 5 minutes.
- This pasty mixture is extruded through a 0.5 mm screen using an extruder 20 (Caleva).
- the filaments obtained are then spheronized using a spheronizer 250 (Caleva).
- the particles obtained are dried at 40° C. in a fluidized airbed.
- the 300-700 ⁇ m fraction is selected by screening.
- microcapsules obtained at the end of the second step of example 14 were tested in a type II dissolutest in accordance with the Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- the dissolution profiles are presented in FIG. 12 .
- microcapsules obtained at the end of the second step of example 14 were tested in a type II dissolutest in accordance with the Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
- the dissolution profiles are presented in FIG. 13 .
- microunits of acyclovir are prepared, in which microunits:
- microcapsules of example No. 10 begin to rapidly release their content above pH>5.5 (use of Eudragit® L100-55).
- microcapsules of example No. 12 begin to rapidly release their content above pH>6.5 (use of 67% Eudragit® L100-55 and 33% Eudragit® S 100 ).
Abstract
The field of the invention is that of oral medicaments or pharmaceutical compositions, in particular of the type including one or more active principles. The aim of the invention is to provide an improved oral medicament to be administered in one or several daily doses and enabling the modified release of active principles (in particular of one active principle), whereby the prophylactic and therapeutic effectiveness of said medicament is improved. This aim is achieved by the oral multimicrocapsule galenic form according to the invention, in which the active principle release is controlled by a dual release trigger mechanism: “time-dependent trigger” and “pH-dependent trigger”. Said medicament includes microcapsules providing the modified release of the active principle, each comprising a core containing
Description
- The field of the present invention is that of micro-particulate systems for the delayed and controlled release of active principle(s) AP(s), for oral administration.
- The APs envisioned in the present invention are in particular those which have an absorption essentially limited to the upper parts of the gastrointestinal tract, located upstream of the colon (of the ileocecal junction), and which represent a large majority of pharmaceutical active principles. The active principles most especially targeted are “low-solubility” active principles.
- More specifically, the invention relates to a microparticulate galenic form for delayed and controlled release, for which the controlled release phase is triggered in a definite manner by means of a double mechanism: “time-dependent” release triggered after a certain period of time spent in the stomach and “pH-dependent” release triggered by a change in pH when the particles enter the small intestine and which begins without any lag time. The microparticles of the present invention are microcapsules containing at least one active principle (AP)— with the exclusion of carvedilol—, having a particle size of less than 2000 microns, individually coated with a coating film for the delayed and controlled release of the AP.
- The invention also relates to the microcapsules for the modified release of at least one active principle, taken as such.
- In the present disclosure, the expression “low-solubility active principle” denotes any active principle, with the exclusion of carvedilol, which has a solubility of less than or equal to approximately 50 g/l, preferably less than or equal to approximately 20 g/l, even more preferably less than or equal to approximately 5 g/l and, for example, less than or equal to 0.1 g/l.
- In the present disclosure, the term “microcapsules” denotes microparticles of active principle, coated with at least one coating for the modified release of at least one active principle (in particular, a low-solubility active principle).
- In the present disclosure, the term “carvedilol” denotes carvedilol per se, one or more pharmaceutically acceptable salts of carvedilol or one or more pharmaceutically acceptable esters of carvedilol, or any mixture of these active agents.
- In the present disclosure, the expression “modified release” denotes, without distinction, a prolonged release of the active principle(s), beginning as soon as the microcapsules are brought into contact with the dissolving medium and extending from 0.5 h to 24 h, preferably 1 h to 10 h, or a release of the active principle(s) that begins only after a predetermined period (lag time) ranging, for example, from 0.5 to several hours, with a release time for 50% of the active principle(s) which is typically several hours and which can extend from 0.5 to 30 hours, for example.
- In the present disclosure, the expression “immediate release” denotes a release of the active principle(s) that begins as soon as the galenic form is brought into contact with the dissolving medium (in vivo or in vitro) with a release time for 80% of the active principle(s) which is less than or equal to 1 h, and for example less than or equal to 20 min.
- Systems for the delayed and controlled release of active principle(s) are particularly useful when it is desirable, for chronobiological reasons, for the active principle(s) to be “bioabsorbed” at a specific time of the day in order to be in phase with the circadian cycle. It may, for example, be advantageous for the active principle(s) to be bioabsorbed very early in the morning in order to ensure therapeutic cover when the patient wakes up, without however restricting the latter to an early wake-up. To do this, the galenic system ingested by the patient, for example in the evening after the evening meal, should allow a delayed release of the active principle(s).
- In the knowledge that another obligatory rule for the specialist in galenics is to guarantee that the medicament prescribed will be absorbed by the patient, it is essential, in the case of a delayed-release form, to have a complete guarantee of release of the active principle at a given moment so as to obtain the therapeutic effect. Now, it must be noted that the delayed-release forms that existed up until recently could not definitely ensure the release of the AP in a stipulated time period, which can be vital for the patient in certain pathologies, for instance that of cardiovascular diseases.
- Another desired property for systems for the delayed and controlled release of active principle(s) is an improvement in the plasma concentration profile obtained after administration. The intended aim is to obtain a plasma profile which is maintained above the effective therapeutic concentration, for as long as possible, in order to maximize the duration of action of the active principle(s), and therefore its (their) therapeutic effectiveness. This aim comes up against the residence time of the active principle(s) in the blood compartment, which is most commonly much less than one day. In order to achieve this aim, it would therefore be advisable to prolong the bioabsorption time of the active principle(s) AP(s) by judicious adjustment of the release of the active principle(s) in front of its (their) bioabsorption window, in the upper parts of the gastrointestinal tract.
- Various forms for the modified release of active principle(s) have been developed in order to attempt to solve the abovementioned problems of chronotherapy and of maintenance of a high plasma profile for as long as possible.
- pH-dependent delayed-release forms are thus known, which are obtained by coating the active principle(s) by means of a layer of enteric polymer, for example of copolymer of methacrylic acid and methacrylic acid methyl ester: EUDRAGIT® L. This type of enteric coating is known to provide a reduced permeability under the acidic pH conditions of the stomach and to dissolve when the pH goes back up to a value close to that which occurs in the small intestine, thus releasing the active principle(s). However, intra- and inter-individual variability in gastric pH conditions and in the duration of gastric emptying do not make it possible to definitely ensure the release of the active principle(s) after a given period of time.
- Delayed-release systems that are purely dependent on the time after ingestion (“time-dependent”), i.e. systems for which the release of the active principle(s) is triggered after a given period of time spent in the gastrointestinal tract, are, moreover, known and are not satisfactory either. In fact, due to the intra- and interindividual variability in gastric residence time, the release of the active principle(s) can take place after the latter has passed in front of its absorption window, which is located, for most active principles, in the upper parts of the gastrointestinal tract. The bioabsorption can thus be very low, or even zero.
- However, it wasn't until the multimicroparticulate galenic system as disclosed in PCT patent application WO-A-03/030878 that very significant progress was obtained, in particular with regard to the abovementioned problems of chronotherapy and of maintenance of a high plasma profile for as long as possible. This system for the delayed, controlled and definite release of the active principle(s) is characterized by a dual mechanism for triggering the release of the active principle(s): “time-dependent” release triggered after a controlled period in the stomach, without any change in pH, and “pH-dependent” release triggered by a raised pH, when the galenic form penetrates the intestine. These two triggering factors for the release of the active principle(s) are placed in series and confer very safe use on the galenic system. The release of the active principle(s) is thus guaranteed after a precontrolled lag time, even if the variation in pH has not intervened as triggering factor, i.e. even if the galenic form has not passed from the stomach to the intestine. These microcapsules of diameter between 200 and 600 microns are characterized by a coating film based on a hydrophilic polymer A of EUDRAGIT®L type combined with a hydrophobic compound B, such as a plant wax (LUBRITAB®) with a melting temperature of between 40 and 90° C., the ratio B/A=0.2-1.5. These microcapsules have an in vitro dissolution behavior such that, at constant pH 1.4, a lag phase of between 1 and 5 hours is observed, followed by an active principle release phase, and such that the change from pH 1.4 to pH 6.8 brings about release of the active principle without any lag time in vitro.
- The multimicroparticulate galenic system according to PCT patent application WO-A-03/030878 also makes it possible to adjust the lag time preceding the release of the AP in the stomach by taking into consideration the physiological conditions of the gastrointestinal tract in humans. This advantageous method is thus a means of minimizing the interindividual variability of absorption of the AP. In fact, according to the well-known results of Davis et al., J. of Controlled Release, 2, 27-38 (1985), the residence time, in the stomach, of a preparation is very variable, of the order of from 0.5 to 10 hours. Now, specifically, the abovementioned system makes it possible to release the active principle in the stomach after a given constant lag time within this range of 0.5-10 hours, such that, from one individual to the other, or even from one day to the other for the same individual, the medicament action time is the same.
- In fact, the microparticulate oral galenic form for the delayed and controlled release of AP, according to WO-A-03/030878, simultaneously has the following properties:
-
- the release of the AP can be triggered in two ways:
- by “time-dependent” release when the amount of time that the particles spend in the stomach exceeds a period of 5 hours;
- by “pH-dependent” release, which begins without any lag time when the system penetrates the intestine and the pH increases. These two AP-release-triggering factors placed in series guarantee release of the AP after a precontrolled lag time, even if the variation in pH has not intervened as triggering factor;
- it consists of a plurality of small microcapsules of coated AP;
- the mass fraction of coating excipients is limited.
- the release of the AP can be triggered in two ways:
- It should be noted that the problem of maintaining a high plasma profile for as long as possible can be solved, in accordance with the invention according to WO-A-03/030878, by using a mixture of microcapsules having different delayed and controlled release profiles. This makes it possible to produce release profiles which exhibit several waves of release or which ensure, by means of an appropriate control of the various fractions, a constant level of plasma concentration of the active principle(s).
- It nevertheless remains that this microparticulate oral galenic form for the delayed and controlled release of active principle(s), according to WO-A-03/030878, can be further improved.
- In fact, it is known that, in order to be released, a microencapsulated active principle must first of all be reached by the fluids of the gastrointestinal tract, which, in order to do this, must cross the coating film of the microcapsules. The microencapsulated active principle can then dissolve in these fluids. The active principle solution thus obtained can subsequently diffuse out of the microcapsules through the coating film(s) of said microcapsules. Thus, in order to obtain a lag time of between 0.5 and 7 h, for example of 2-3 h, it is important for the coating film of the microcapsules to have a sufficient thickness (in μm) and/or to represent a sufficient degree of film-coating DF (in % by weight) so that the entry time of a liquid such as water or a gastrointestinal tract fluid into the microcapsule allows delayed release of the active principle. This minimum thickness can, for example, correspond to a DF of 10-40%, for example.
- However, when the thickness of the film-coating is sufficient to result in a lag time, it is possible to note that, in the case of low-solubility active principles, the “time-dependent” release, just like the “pH-dependent” release, of the active principle is still as effective, but becomes slower, which can be detrimental to the bioavailability. For example, at least 80% by weight of the active principle is not released after, for example, 16 h at pH=7.0 in an in vitro dissolution test carried out according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm.
- There exists, therefore, to date a need for a pharmaceutical composition or a multimicrocapsule oral medicament, for the modified release of active principle(s), which is of the type of those disclosed in WO-A-03/030878 and which improves the latter, making it possible in particular to obtain, for low-solubility active principles, release of the active principle according to a dual “time-dependent” and “pH-dependent” trigger mechanism, with more rapid release times which make it possible to optimize the bioabsorption of the active principle(s), regardless of the mechanism for triggering this release.
- One of the essential objectives of the invention is to provide an oral medicament that is improved in relation to that described in WO-A-03/030878, specifically a multimicrocapsule oral medicament for the modified release of active principle(s), in particular of low-solubility active principle(s), which guarantees correct functioning of the dual “time-dependent” and “pH-dependent” trigger mechanism for the release of the active principle, in particular for low-solubility active principles.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s) that makes it possible to judiciously adjust the release kinetics of the active principle all along its window of absorption in the gastrointestinal tract so that the plasma concentration profile is maintained above the effective therapeutic concentration for as long as possible, and in particular for a period of time greater than that of the immediate-release form.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which provides a suitable solution to the problem of chronotherapy and to the difficulties of compliance relating thereto.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which makes it possible to readily combine at least two active principles in the same pharmaceutical form.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which, contrary to the compact monolithic forms, offers a reduced interindividual variability.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which allows an increase in the gastrointestinal transit time and absorption of the active principle in the upper parts of the gastrointestinal tract.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), it being possible for this medicament to exist in a presentation form that can be administered once a day, which would represent significant progress, in particular in terms of patient compliance.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which can be produced according to a sound industrial process.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which is easy to prepare, for example by deposition of a coating by spraying onto microparticles containing low-solubility active principle.
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which is capable of having high contents of active principle(s), for example up to 60% by weight of the microcapsules.
- Another essential objective of the invention is to provide an oral medication for the modified release of active principle(s), which contains a plurality of microcapsules and has a dose-independent in vitro active principle release profile.
-
- Another essential objective of the invention is to provide a multimicrocapsule oral medicament for the modified release of active principle(s), which makes it possible to obtain a plasma concentration (C24h) of active principle(s) 24 h after oral administration which is as high as possible.
- Another essential objective of the invention is to provide microcapsules for the modified release of active principles, which can be used in particular for preparing a medicament as defined by the specifications stated in the above objectives.
- These objectives, among others, are achieved by means of the invention which relates, firstly, to an oral medicament comprising a plurality of microcapsules for the modified release of active principle(s), at least some of said microcapsules consisting individually of a microparticle comprising at least one active principle, in particular at least one low-solubility active principle (with the exclusion of carvedilol), coated with at least one coating for the modified release of the active principle(s), said release being controlled by two distinct trigger mechanisms, one being based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of time spent in the stomach,
- said coating also conferring on the microcapsules an in vitro dissolution behavior such that:
-
- at constant pH 1.4, the dissolution profile comprises a lag phase less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably between 1 and 5 hours, in duration;
- the passing from pH 1.4 to pH 7.0 results in a release phase which begins without any lag time;
this medicament being characterized
in that at least some of said microcapsules comprise at least one swelling agent,
and in that the fraction by weight of the active principle(s) released during the lag phase is less than or equal to 15% by weight per hour, preferably less than or equal to 10% by weight per hour, and even more preferably less than or equal to 5% by weight per hour.
- The in vitro dissolution behavior is determined according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm.
- The medicament according to the invention overcomes the abovementioned technical problem, i.e. the release of low-solubility active principle(s) AP(s) according to a dual “time-dependent” and “pH-dependent” trigger mechanism, thereby accelerating the release of the active principle, in particular compared with the release times obtained by the invention according to WO-A-03/030878. In doing so, the medicament according to the invention ultimately improves the prophylactic and therapeutic efficacy of such low-solubility active principles.
- However, the medicament according to the invention is also advantageous in that it offers in particular the following advantages:
- possibility of simple combined use of at least two active principle(s);
- reduced interindividual variability;
- increase in gastrointestinal transit time and absorption of the active principle in the upper parts of the gastrointestinal tract;
- proportionality between the dose and the pharmacokinetic profile;
- ease of ingestion by the patient and possibility of administration, for example once a day, which ensures that compliance is observed and therefore guarantees efficacy;
- reproducibility of the release kinetics, from one industrial batch to the other; industrial development is therefore possible, without this harming the therapeutic performance levels of the encapsulated active principle(s) (for example, low-solubility active principles);
- easy and economical preparation, for example by deposition of a coating by spraying onto microparticles containing low-solubility active principle;
- possibility of having high contents of active principle(s), for example up to 60% by weight of the microcapsules;
- plurality of microcapsules and having a dose-independent in vitro active principle release profile;
-
- plasma concentration of active principle(s) 24 h after oral administration close to or greater than that which would be obtained with an immediate-release form taken in several doses.
- In accordance with the invention, the swelling agent comprises at least one hydrophilic pharmaceutically acceptable compound which exhibits a degree of swelling in water at 25° C. of greater than or equal to 10% by weight, preferably greater than or equal to 15% by weight, and even more preferably greater than or equal to 20%.
- According to a notable characteristic of the invention, the swelling agent is chosen from those which allow the microcapsules to release at least 50% by weight of the active principle, after 16 h at pH=1.4, and after a lag phase of less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably between 1 and 5 hours in duration, in an in vitro dissolution test carried out according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm.
- In accordance with the invention, it is possible to adjust the rate of release at pH=1.4 of the active principle(s) from the microcapsules by judiciously selecting the concentration (Cd) of swelling agent.
- When the swelling agent is in microparticulate form, the size (Td) of the particles of swelling agent is advantageously selected within the average diameter ranges, in μm, of between 5 and 200 μm, and preferably between 10 and 50 μm.
- The concentration (Cd) of swelling agent is selected within the following ranges of % by weight relative to the total mass of the microcapsules:
- 3≦Cd≦40,
- preferably, 4≦Cd≦30,
- and even more preferably, 5≦Cd≦25.
- According to a preferred embodiment of the invention, the swelling agent is chosen from the group of following products:
-
- crosslinked polyvinylpyrrolidones (e.g. polyplasdone or crospovidone),
- crosslinked carboxyalkylcelluloses: crosslinked carboxymethylcelluloses (e.g. crosslinked sodium croscarmellose),
- and also high molar mass hydrophilic polymers (greater than or equal to 100 000 D) such as:
- polyvinylpyrrolidones,
- polyalkylene oxides (e.g. polyethylene oxide or polypropylene oxide),
- (hydroxy)(alkyl)celluloses (e.g. hydroxypropylcellulose, hydroxypropylmethylcellulose),
- carboxyalkylcelluloses (e.g. carboxymethylcellulose),
- celluloses (powder or microcrystalline),
- modified starches (for example modified with sodium glycolate),
- natural starches (for example from maize, wheat or potato),
- sodium alginate,
- potassium polacriline,
- and mixtures thereof.
- Even more preferably, the swelling agent is chosen from the subgroup of following products:
-
- crosslinked polyvinylpyrrolidones (e.g. polyplasdone or crospovidone), and
- crosslinked carboxyalkylcelluloses: crosslinked carboxymethylcelluloses (e.g. crosslinked sodium croscarmellose).
- In order to overcome the eventuality in which active principles (for example, low-solubility active principles) would be poorly wetted by water and would therefore have a tendency to agglomerate, it is proposed, according to an advantageous variant of the invention, to make sure that the medicament comprises at least one wetting agent, preferably chosen from the group of following products:
-
- anionic surfactants, preferably in the subgroup of alkali metal or alkaline earth metal salts of fatty acids, stearic acid and/or oleic acid being preferred,
- and/or nonionic surfactants, preferably in the following subgroup:
- polyoxyethylenated oils, preferably polyoxyethylenated hydrogenated castor oil,
- polyoxyethylene-polyoxypropylene copolymers,
- polyoxyethylenated sorbitan esters,
- polyoxyethylenated castor oil derivatives,
- stearates, preferably calcium stearate, magnesium stearate, aluminum stearate or zinc stearate,
- stearyl fumarates, preferably sodium stearyl fumarate,
- glyceryl behenate,
- and mixtures thereof.
- Advantageously, the medicament according to the invention comprises microcapsules of active principle(s), capable of releasing at least 80% by weight of the active principle(s), after 12 h at pH=7.0, in an in vitro dissolution test carried out according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm.
- The medicament according to the invention is multimicrocapsular, i.e. it comprises, inter alia, microcapsules consisting of microparticles of coated or film-coated active principle. These microparticles of active principle may be, for example, crude (pure) active principle in pulverulent form, matrix granules of active principle with various other ingredients, or alternatively neutral microspheres, for example made of cellulose or of sugar, coated with at least one layer comprising active principle.
- The modified-release microcapsules of active principle can be compared to microunits containing at least one active principle and forming at least some of the constitutive elements of the medicament according to the invention.
- Each microcapsule can contain one or more active principles that are identical to or different than one another.
- The medicament according to the invention can comprise microunits of active principle other than microcapsules. They could, for example, be microcapsules for the immediate release of active principle(s). The latter may, for example, be uncoated microparticles of active principle(s) of the same type as those that can be used in the preparation of the microcapsules according to the invention.
- Each microparticle can comprise one or more active principles that are identical to or different than one another.
- In addition, the collection of microunits (microparticles and/or microcapsules) constituting the medicament according to the invention can be made up of various populations of microunits, these populations differing from one another at least by virtue of the nature of the active principle(s) contained in these microunits and/or by virtue of the composition of the coating.
- As regards the structure of the microcapsules used in the medicament according to the invention, two preferred embodiments of the structure of the microcapsules are described in detail hereinafter, in a nonlimiting capacity.
- According to a first embodiment, at least some of the microcapsules for the modified release of active principle(s) each comprise:
-
- a microparticle of active principle(s), coated with
- at least one coating for the modified release of the active principle(s).
- Preferably, the microparticle of active principle(s) is a granule comprising the active principle(s) and one or more pharmaceutically acceptable excipients.
- Advantageously, the swelling agent(s) is (are) contained in the microparticle (e.g. granule).
- As regards the wetting agent(s), it (they) is (are) preferably contained in the microparticle (e.g. granule) and/or in the coating for the modified release of the active principle(s).
- According to a second embodiment, at least some of the microcapsules for the modified release of active principle(s) each comprise:
-
- a neutral core,
- at least one active layer comprising the active principle(s) and coating the neutral core, and
- at least one coating for the modified release of the active principle(s).
- According to a first possibility, the neutral core contains sucrose and/or dextrose and/or lactose.
- According to a second possibility, the neutral core is a cellulose microsphere.
- Advantageously, the neutral core has an average diameter of between 1 and 800 μm, and preferably between 20 and 500 μm.
- The active layer can optionally comprise, in addition to the active principle(s), one or more pharmaceutically acceptable excipients.
- Advantageously, the swelling agent(s) is (are) contained in the active layer.
- For example, this active layer comprises active principle, at least one swelling agent, at least one binder and at least one surfactant.
- As regards the wetting agent(s), it (they) is (are) preferably contained in the active layer.
- With regard now to the composition of the coating of the microcapsules for the modified release of active principle(s), the present invention also consists in selecting microcapsules having the following specificities:
-
- the coating for the modified release of the active principle(s) comprises a composite material
- comprising:
- at least one hydrophilic polymer A bearing groups that are ionized at neutral pH,
- at least one hydrophobic compound B,
- representing a mass fraction (% weight relative to the total mass of the microcapsules)≦40; and
- comprising:
- their average diameter is less than 2000 μm, and preferably between 50 and 800 μm, and even more preferably between 100 and 600 μm.
- the coating for the modified release of the active principle(s) comprises a composite material
- According to another advantageous characteristic, the composite material AB of the coating for the modified release of the low-solubility active principle is such that:
-
- the weight ratio B/A is between 0.2 and 1.5, preferably between 0.5 and 1.0,
- and the hydrophobic compound B is selected from products that are crystalline in the solid state and have a melting point MpB≧40° C., preferably MpB≧50° C., and even more preferably 40° C.≦MpB≦90° C.
- According to a favored embodiment, the hydrophilic polymer A is chosen from:
-
- A.a copolymers of (meth)acrylic acid and of a (meth)acrylic acid alkyl ester, and mixtures thereof;
- A.b cellulose derivatives, preferably cellulose acetates, cellulose phthalates, cellulose succinates and mixtures thereof, and even more preferably hydroxypropylmethylcellulose phthalates, hydroxypropylmethylcellulose acetates, hydroxypropylmethylcellulose succinates and mixtures thereof;
- and mixtures thereof.
- The polymers A that are even more preferred are copolymers of (meth)acrylic acid and of (meth)acrylic acid alkyl (e.g. C1-C6 alkyl) esters. These copolymers are, for example, of the type such as those sold by the company Röhm Pharma Polymers under the registered trademarks EUDPAGIT®, of the series L and S (such as, for example, EUDRAGIT® L100, S100, L30 D-55 and L100-55). These copolymers are anionic enteric copolymers that are soluble in an aqueous medium at pHs above those encountered in the stomach.
- Still according to the favored embodiment, the compound B is chosen from the group of following products:
-
- B.a plant waxes taken on their own or as mixtures with one another;
- B.b hydrogenated plant oils taken on their own or as mixtures with one another;
- B.c mono- and/or di- and/or triesters of glycerol and of at least one fatty acid;
- B.d mixtures of monoesters, of diesters and of triesters of glycerol and of at least one fatty acid;
- B.e and mixtures thereof.
- Even more preferably, the compound B is chosen from the group of following products: hydrogenated cottonseed oil, hydrogenated soya bean oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin, yellow wax, hard fat or fat that can be used as bases for suppositories, anhydrous dairy fats, lanolin, glyceryl palmitostearate, glyceryl stearate, lauryl macrogolglycerides, cetyl alcohol, polyglyceryl diisostearate, diethylene glycol monostearate, ethylene glycol monostearate, Omega 3 and any mixture thereof,
- preferably from the subgroup of following products: hydrogenated cottonseed oil, hydrogenated soya bean oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin and any mixture thereof.
- In practice, and without it being limiting, compound B is preferably chosen:
-
- from the group of products sold under the following trademarks: Dynasan®, Cutina®, Hydrobase®, Dub®, Castorwax®, Croduret®, Compritol®, Sterotex®, Lubritab®, Apifil®, Akofine®, Softtisan®, Hydrocote®, Livopol®, Super Hartolan®, MGLA®, Corona®, Protalan®, Akosoft®, Akosol®, Cremao®, Massupol®, Novata®, Suppocire®, Wecobee®, Witepsol®, Lanolin®, Incromega®, Estaram®, Suppoweiss®, Gelucire®, Precirol®, Emulcire®, Plurol diisostearique®, Geleol®, Hydrine® and Monthyle® and mixtures thereof;
- and also from the group of additives for which the codes are the following: E 901, E 907, E 903 and mixtures thereof;
- and, preferably from the group of commercial products sold under the following trademarks: Dynasan® P60, Dynasan® 114, Dynasan® 116, Dynasan® 118, Cutina® HR, Hydrobase® 66-68, Dub® HPH, Compritol® 888, Sterotex® NF, Sterotex® K, Lubritab® and mixtures thereof.
- According to another advantageous characteristic of the invention, the coating for the modified release of the low-solubility active principle is free of talc.
- According to another notable characteristic that is the result of the preparation of the microcapsules, the active principle is deposited onto the core by techniques known to those skilled in the art, for example the fluidized air bed spray coating technique, wet granulation, compacting, extrusion-spheronization, etc.
- Advantageously, the coating of the microcapsules can comprise, in addition to the essential constituents A and B, other conventional ingredients known to those skilled in the art, such as, in particular:
-
- dyes,
- plasticizers, for instance dibutyl sebacate,
- hydrophilic compounds, for instance cellulose and derivatives thereof or polyvinylpyrrolidone and derivatives thereof,
- and mixtures thereof.
- Without it being limiting and according to an even more preferred embodiment, the coating of the microcapsules for the modified release of active principle comprises a single composite AB coating film.
- In quantitative terms, the monolayer of coating can represent, for example, at most 40%, preferably at most 30% by weight of the microcapsules. Such a limited degree of coating makes it possible to prepare galenic units that each contain a high dose of active principle, without exceeding a size that would be completely unacceptable with regard to swallowing. The compliance with and therefore the success of the treatment can only be improved by this.
- The mechanism for triggering the release of the low-solubility active principle without any variation in pH, after a predetermined residence time in the stomach, results in particular from the control of the rate of hydration of the microcapsules and/or of the dissolution of one or more components of the microcapsules. For example, and without wishing to be limiting, the hydration of the microcapsule can be controlled:
-
- by the presence, in the microcapsules, of hydrophilic products which make it possible to adjust the osmotic pressure or to cause swelling of the microcapsules;
- or by regulating the water-permeability of the coating film;
- or by creating a microporosity in the coating film;
- or even by hydration or dissolution of a compound of the coating film.
- One of the determining advantages of the multimicrocapsule galenic system for the delayed and controlled release of active principle(s), for example of low-solubility principle(s), according to the invention, is to involve, in vivo, two factors that trigger the release of the active principle(s), for example of the low-solubility principle(s), in the gastrointestinal tract, i.e.:
-
- the period of time spent in the stomach: “time-triggered” release,
- the variation in pH: “pH-triggered” release.
- These two factors that trigger the release of active principle(s), for example of low-solubility principle(s), are in series such that they confer very safe use on the galenic system. The release of the active principle(s), for example of the low-solubility principle(s), is thus guaranteed after a precontrolled lag time, even if the variation in pH has not intervened as triggering factor. The problems of interindividual variability are thus overcome. The therapeutic efficacy of the medicament comprising such a galenic system is ensured, observing a predetermined chronobiology adapted to the targeted therapeutic performance level.
- In addition, for any active principle (e.g. low-solubility active principle) the window of absorption of which is limited to the upper parts of the gastrointestinal tract, it is particularly advantageous for the form for the delayed and then prolonged and controlled release to be made up of a plurality of microcapsules. In fact, for such a galenic form, the dose of active principle (e.g. low-solubility active principle) to be administered is divided up between a large number of microcapsules (typically 5000-50 000) and as a result provides the following intrinsic advantages:
-
- The period of time spent by the microcapsules in the upper parts of the gastrointestinal tract can be prolonged, thereby ensuring an increase in the amount of time spent by the low-solubility active principle in passing before the windows of absorption and thus maximizing the bioavailability of the low-solubility active principle.
- The use of a mixture of microcapsules with different delayed- and controlled-release profiles makes it possible to produce release profiles which have several waves of release or which ensure, through an appropriate control of the various fractions, a constant level of plasma concentration of the low-solubility active principle.
- There is less variability in the gastric emptying since the emptying which takes place here over a large number of particles is statistically more reproducible.
- Contact between the tissues and a high dose of low-solubility active principle, “dose dumping”, is prevented. Each microcapsule in fact contains only a very low dose of low-solubility active principle. One is thus free of the risk of tissue deterioration due to local overconcentration of aggressive low-solubility active principle.
- It is possible to provide these microcapsules in the form of a sachet, gelatin capsule or tablet. When the dose of low-solubility active principle is high (500 mg or more), monolithic forms are too large in size to be readily swallowed. It is then particularly advantageous to have a microparticulate form which ensures the delayed and controlled release of the active principle (in particular low-solubility active principle) and which those skilled in the art can produce in the form of disintegratable tablets or of sachets.
- The multimicrocapsule galenic system according to the invention makes it possible to ensure, in a reliable manner, a delayed and controlled release of the low-solubility active principle in the gastrointestinal tract by virtue of two triggers, and to thus escape the inter- and intraindividual variability of the conditions of gastric emptying, while at the same time being economically viable and easy to ingest (optimized compliance).
- Another subject of the invention relates to an oral medicament comprising a plurality of microcapsules for the modified release of active principle(s), at least some of said microcapsules consisting individually of a microparticle comprising at least one active principle, in particular at least one low-solubility active principle (with the exclusion of carvedilol), coated with at least one coating for the modified release of the active principle(s), said release being controlled by two distinct trigger mechanisms, one based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of time spent in the stomach,
- said coating:
-
- also conferring on the microcapsules an in vitro dissolution behavior (produced according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm), such that:
- at constant pH 1.4, the dissolution profile comprises a lag phase less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably between 1 and 5 hours, in duration;
- at least 50% by weight of the active principle(s) is released after 16 h at pH 1.4;
- the passing from pH 1.4 to pH 7.0 results in a release phase which begins without any lag time;
- and comprising a composite material comprising at least one hydrophilic polymer A bearing groups that are ionized at neutral pH and at least one hydrophobic compound B;
this medicament being characterized - in that at least some of said microcapsules comprise at least one release helper capable of increasing the permeability of the coating for the modified release of the active principle(s),
- and in that the fraction by weight of the active principle(s) released during the lag phase is less than or equal to 15% by weight per hour, preferably less than or equal to 10% by weight per hour, and even more preferably less than or equal to 5% by weight per hour.
- also conferring on the microcapsules an in vitro dissolution behavior (produced according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm), such that:
- It has in fact appeared to be useful in accordance with the invention to provide for, in the microcapsules, one or more helpers suitable for increasing the permeability of the coating, so as to reduce the release time, in particular for low-solubility active principles.
- Advantageously, the release helper consists of at least one swelling agent, as defined above.
- The medicament according to this other subject of the invention is also remarkable in that the coating of the microcapsules included in this medicament confers on said microcapsules an in vitro dissolution behavior (produced according to the indications of the European Pharmacopeia 4th edition, entitled: “Dissolution test for solid oral forms”: type II dissolutest carried out under SINK conditions, maintained at 37° C. and stirred at 100 rpm),
- such that at least 50% by weight of the active principle(s) is released after 16 h at pH 1.4.
- The fact that the medicament according to the invention consists of a plurality of microunits makes it possible to obtain another essential characteristic of the invention, according to which the medicament comprises a mixture of various populations of microunits containing active principle(s) (with the exclusion of carvedilol), these populations differing from one another by virtue of their respective in vitro dissolution profiles, for at least one pH value of between 1.4 and 7.4.
- This essential characteristic makes it possible to obtain an increase in the bioabsorption time of the active principle(s) and therefore in the time during which the plasma concentration is greater than the minimum effective concentration of this active principle.
- In fact, the mixture of various populations of microunits (e.g. microcapsules for the modified release of active principle and, optionally, microparticles for the immediate release of active principle) brings about a preferential release of the active principle(s) at different sites of the gastrointestinal tract, over the entire extent of the window of bioabsorption of the active principle(s) in the gastrointestinal tract.
- According to an advantageous embodiment of this characteristic of a mixture of various populations of microunits, the medicament according to the invention is characterized in that the microunits are microcapsules for the modified release of active principle(s) and, optionally, microunits for the immediate release of active principle(s).
- Advantageously, the populations of microcapsules for the modified release of active principle(s) differ by virtue of their respective trigger pHs.
- The populations of microcapsules for the modified release of active principle(s) can differ not only by virtue of their respective trigger pHs, but also by virtue of their respective trigger times, or even by virtue of their respective trigger pHs and times.
- According to a preferred embodiment of this characteristic of a mixture of populations, the medicament comprises:
- i. at least one population of microunits containing immediate-release active principle;
- ii. at least one population P1 of microcapsules for the modified release of active principle(s); and
- iii. at least one population P2 of microcapsules for the modified release of active principle(s);
and, moreover, the respective trigger pHs of P1 and of P2 differ by at least 0.5 pH unit, preferably by at least 0.8 pH unit, and even more preferably by at least 0.9 pH unit. - According to a preferred arrangement relating to the trigger pHs that differentiate the various populations of microcapsules for the modified release of active principle(s), said respective trigger pHs are between 5 and 7.
- According to another variant of the preferred embodiment of this characteristic of a mixture of populations, the medicament comprises:
- i. at least one population of microunits containing immediate-release active principle(s);
- ii. at least one population P1′ of microunits containing active principle(s) made up of microcapsules for the modified release of the active principle(s), the trigger pH of which is equal to 5.5; and
- iii. at least one population P2′ of microunits containing active principle(s) made up of microcapsules for the modified release of the active principle(s), the trigger pH of which is equal to 6.0 or 6.5.
- The release profile (measured in an in vitro release test as defined above) of the modified-release microcapsules used in the abovementioned mixtures of various populations of microunits (for example, P1 and P2 or P1′ and P2′) may, for example, be as indicated hereinafter:
- less than 20% of the active principle(s) is released after 2 hours at pH=1.4;
- at least 50% of the active principle(s) is released after 16 hours at pH=1.4.
- When the medicament according to the invention comprises at least one population of microunits containing immediate-release active principle(s), this population can advantageously be defined by its behavior in an in vitro dissolution test, said behavior being such that at least 80% of the active principle(s) is released in 1 hour at any pH between 1.4 and 7.4.
- According to an advantageous characteristic of the invention, the proportion of low-solubility active principle(s) in the microunits containing active principle(s) (expressed as % by weight on a dry weight basis, relative to the total mass of the microunits) is between 5 and 80, preferably between 10 and 70, and even more preferably between 15 and 60.
- Preferably, the microunits containing immediate-release active principle(s) are uncoated microparticles.
- Without wishing to be limiting, it should nevertheless be underlined that the medicament according to the invention is particularly advantageous in that it can be in the form of a single daily oral dose comprising:
-
- from 5000 to 500 000 microunits containing active principle(s), or
- from 5000 to 500 000 microcapsules for the modified release of active principle(s).
- This plurality of microcapsules, illustrated by the numeric examples mentioned above, constitutes a galenic form that is entirely well tolerated by the mammalian organism.
- These microcapsules are all the more advantageous since they are manufactured simply and economically according to techniques well known to those skilled in the art, for example the fluidized air bed spray coating technique, wet granulation, compacting, extrusion-spheronization, etc.
- For further details on the preparation of these microcapsules, in particular in their preparation form with a neutral core coated with at least one active layer comprising active principle(s) and with at least one outer coating for the modified release of the active principle(s), reference will be made to the content of PCT application WO-A-FR03/030878, the content of which is integrated into the present disclosure by way of reference.
- The medicament in multimicroparticulate oral galenic forms according to the invention can be a tablet, advantageously an orodispersible tablet, a powder, a liquid suspension or a gelatin capsule containing microcapsules.
- In other words, this medicament can be in the form of a sachet of microcapsule powder, of a liquid suspension of microcapsules, of a tablet obtained from microcapsules or a gelatin capsule containing microcapsules.
- These tablets, these gelatin capsules, these powders and these suspensions can consist of mixtures of the various populations of microunits, and in particular of microcapsules of active principle(s) according to the invention, preferably combining therewith microunits or microparticles for the immediate release of low-solubility active principle (for example granules).
- Moreover, the invention is directed toward the use of the microcapsules for the modified release of active principle(s) as defined above and, optionally, of microunits containing immediate-release active principle(s), for the preparation of pharmaceutical or dietetic, microparticulate oral galenic forms, preferably in the form of advantageously orodispersible tablets, of powders or of gelatin capsules.
- Furthermore, the invention relates to the microcapsules as defined above, taken as such.
- Preferably, the active principle(s) can be chosen from at least one of the following major varieties of active substances, e.g.: antiulcer agents, antidiabetic agents, anticoagulants, antithrombotics, blood-lipid-lowering agents, antiarrhythmics, vasodilators, anti-angina agents, antihypertensives, vasoprotectors, fertility promoters, inhibitors and inducers of uterine labor, contraceptives, antibiotics, antifungals, antivirals, anticancer agents, anti-inflammatories, analgesics, antiepileptics, antiparkinsonian agents, neuroleptics, hypnotics, anxiolytics, psychostimulants, antimigraine agents, antidepressants, antitussives, antihistamines or anti-allergic agents, agents for combating congestive heart failure, angina pectoris, left ventricular hypertrophy, cardiac arrhythmias, myocardial infarction, reflex tachycardia, ischemic heart disease, atheromatosis, diabetes mellitus-related hypertension, portal hypertension, vertigo, abradycardia, arterial hypotension, water and sodium retention, acute renal insufficiency, orthostatic hypotension and cerebral congestion, and mixtures thereof.
- As examples of active principles that may be contained in the medicament according to the invention, mention may be made of those chosen from the group of following compounds: acetylsalicylic acid, carbamazepine pentoxifylline, prazosine, acyclovir, nifedipine, diltiazem, naproxen, ibuprofen, flurbiprofen, ketoprofen, fenoprofen, indomethacin, diclofenac, fentiazac, estradiol valerate, metoprolol, sulpiride, captopril, cimetidine, zidovudine, nicardipine, terfenadine, atenolol, salbutamol, carbamazepine, ranitidine, enalapril, simvastatin, fluoxetine, alprazolam, famotidine, ganciclovir, famciclovir, spironolactone, 5-asa, quinidine, perindopril, morphine, pentazocine, paracetamol, omeprazole, lansoprazole, metoclopramide, aminosalicylic acid, nalidixic acid, amoxicillin, amoxicillin and potassium clavulanate, ampicillin, ampicillin and sulbactam, azithromycin, bacampicillin, carbenicillin-indanyl-sodium (and other carbenicillin salts), capreomycin, cefadroxil, cefazoline, cephalexine, cephalothine, cephapirine, cephacelor, cephprozile, cephadrine, cefamandole, cefonicide, ceforanide, cefuroxime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftaxidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, cefmetazole, cefotetan, cefoxitin, ciprofloxacin, clarithromycin, clindamycin, clofazimine, cloxacillin, cotriamoxazole, cycloserine, dicloxacillin, dirithromycin, erythromycin (and erythromycin salts such as estolate, ethyl succinate, gluceptate, lactobionate, stearate), ethambutol-HCl and other salts, ethionamide, fosfomycin, imipenem, isoniazide, levofloxacin, lomefloxacin, loracarbef, methicillin, methenamine, metronidazole, metoclopramide, mezlocillin, nafcillin, nitrofurantoin, norfloxacine, novobiocine, ofloxacine, oxacillin, penicillin V, penicillin salts, penicillin complexes, pentamidine, piperacillin, piperacillin and tazobactam, sparfloxacine, sulfacytine, sulfamerazine, sulfamethazine, sulfamethixole, sulfasalazine, sulfisoxazole, sulfapyrizine, sulfadiazine, sulfinethoxazole, sulfapyridine, ticarcillin, ticarcillin and potassium clavulanate, trimethoprim, trimetrexate, troleanomycin, vancomycin, verapamil and mixtures thereof.
- According to a specific but nonlimiting variant of the invention, the active principle(s) is (are) one of the low-solubility active principle(s), for example chosen from the active principles as mentioned above (taken by themselves or as a mixture with one another).
- The active principles to which the present invention also relates may also be nutritional and/or dietetic supplements or mixtures thereof, for instance vitamins, amino acids, antioxidants or trace elements, or mixtures thereof.
- Finally, the invention is also directed toward a method of therapeutic treatment, characterized in that it consists of an oral administration, according to a given dosage, of the medicament according to the invention as defined above.
- The invention will be explained more thoroughly by means of the examples hereinafter, given solely by way of illustration in order to fully understand the invention and to reveal its preparation and/or implementation variants.
-
FIG. 1 : in vitro release profiles of the microcapsules prepared according to comparative example 1. -
FIG. 2 : in vitro release profiles of the microcapsules prepared according to comparative example 2. -
FIG. 3 : in vitro release profiles of the microcapsules prepared according to comparative example 3. -
FIG. 4 : in vitro release profiles of the microcapsules prepared according to comparative example 4. -
FIG. 5 : in vitro release profiles of the microcapsules prepared according to example 5 and comparison with the release profiles of the microcapsules prepared according to comparative example 1. -
FIG. 6 : in vitro release profiles of the microcapsules prepared according to example 6 and comparison with the release profiles of the microcapsules prepared according to comparative example 2. -
FIG. 7 : in vitro release profiles of the microcapsules prepared according to example 7 and comparison with the release profiles of the microcapsules prepared according to comparative example 3. -
FIG. 8 : release profiles of the microcapsules prepared according to examples 8, 9 and 10 at pH 1.4. -
FIG. 9 : release profiles of the microcapsules prepared according to examples 8, 9 and 10, measured for 2 h at pH 1.4 and then at pH 6.8. -
FIG. 10 : release profiles of the microcapsules prepared according to examples 10, 11, 12 and 13 at pH 1.4. -
FIG. 11 : release profiles of the microcapsules prepared according to example 14. -
FIG. 12 : release profiles of the microcapsules prepared according to example 15. -
FIG. 13 : release profiles of the microcapsules prepared according to example 16. -
FIG. 14 : release profiles of the microcapsules prepared according to example 17. - The examples below relate to the following active principles:
-
Active principle Solubility (g/l) Spironolactone 0.02 Lansoprazole 0.05 Nitrofurantoin 0.3 Amoxicillin trihydrate 3.0 Acyclovir 10.0 - Comparative example 1 (spironolactone), comparative example 2 (amoxicillin trihydrate), comparative example 3 (nitrofurantoin) and comparative example 4 (carvedilol) illustrate formulations for the delayed and controlled release of the active principle, obtained according to WO-A-03/030878. However, it would be advantageous to conserve the lag phase while at the same time increasing the rate of release after the lag phase, in order to optimize the bioavailability and the efficacy of the active principle. The microcapsules of comparative examples 1 to 4 do not comprise any swelling agent.
- Examples 5 (spironolactone), 6 (amoxicillin trihydrate) and 7 (nitrofurantoin) illustrate formulas according to the invention.
- Examples 8, 9 and 10 (acyclovir) show the influence of the amount of swelling agent present in the formulas on the release kinetics at pH 1.4.
- Examples 11, 12 and 13 (acyclovir) illustrate a nonexhaustive selection of the swelling agents that may be used in the formulas according to the invention.
- Example 14 (acyclovir) illustrates the preparation of microcapsules, combining a wet granulation step and a fluidized air bed coating step.
- Example 15 (acyclovir) illustrates the preparation of microcapsules, combining an extrusion/spheronization step and a fluidized air bed coating step.
- Example 16 (acyclovir) illustrates the preparation of microcapsules, combining a compacting step and a fluidized air bed coating step.
- Example 17 (acyclovir) illustrates the preparation of a medicament composed of the mixture of various types of microunits.
- 432 g of spironolactone and 48 g of low molar mass hydroxypropylcellulose (Klucel® EF/Hercules) are dispersed in 1120 g of purified water. The suspension is sprayed onto 720 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- 43.2 g of hydrogenated cottonseed oil (Penwest) and 64.8 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 492 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in
FIG. 1 . It is noted that: -
- at pH 1.4, the release of the active principle is slow after the lag period of approximately 2 hours;
- when the pH goes from 1.4 to 6.8, the release kinetics accelerate but remain slow (approximately 8 hours are required in order to release 80% of the active principle).
- The novel compositions according to the invention make it possible to accelerate the release profiles at pH 1.4 and at pH 6.8, while at the same time conserving the lag phase at pH 1.4.
- 1620 g of amoxicillin trihydrate and 180 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) are dispersed in 4200 g of purified water. The suspension is sprayed onto 200 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- 120 g of hydrogenated cottonseed oil (Penwest) and 180 g of poly(methacrylic acid) (ethyl acrylate) Acrycoat® L100D (NP Pharm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 700 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in
FIG. 2 . It is noted that: -
- at pH 1.4, the release of the active principle is slow after the lag period of approximately 4 hours;
- when the pH goes from 1.4 to 6.8, the release kinetics are rapid as expected.
- The novel compositions according to the invention make it possible to optimize the release profiles at pH 1.4, while at the same time maintaining a rapid release at pH 6.8 and while at the same time conserving a lag phase at pH 1.4.
- 640 g of amoxicillin trihydrate and 160 g of low molar mass hydroxypropylcellulose (Klucel® EF/Hercules) are dispersed in 2400 g of purified water. The suspension is sprayed onto 200 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- 40 g of hydrogenated cottonseed oil (Penwest), 5 g of dibutyl sebacate (Morflex) and 55 g of poly(methacrylic acid) (methyl methacrylate) Eudragit® L100 (Röhm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 900 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in
FIG. 3 . It is noted that: -
- at pH 1.4, the release of the active principle is slow after the lag period of approximately 2 hours;
- when the pH goes from 1.4 to 6.8, the release kinetics are rapid as expected.
- The novel compositions according to the invention make it possible to optimize the release profiles at pH 1.4, while at the same time maintaining a rapid release at pH 6.8 and while at the same time conserving a lag phase at pH 1.4.
- 1120 g of carvedilol phosphate and 280 g of Plasdone K29/32® (ISP) are dispersed in 1120 g of purified water. The suspension is sprayed onto 600 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater.
- 100 g of hydrogenated cottonseed oil (Penwest) and 150 g of Eudragit® L100-55 (Röhm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the Pharmacopoeia, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in the attached
FIG. 4 . It is noted that: -
- at pH 1.4, the release of the active principle is slow after the lag period of approximately 2 hours;
- when the pH goes from 1.4 to 6.8, the release kinetics accelerate, but remain slow (at 16 hours, only 40% of the active principle has been released).
- 216 g of spironolactone, 72 g of low molar mass hydroxypropylcellulose (Klucel® EF/Hercules), 72 g of PEG-40 hydrogenated castor oil (
Cremophor RH 40/BASF) and 360 g of crospovidone (Kollidon CL/BASF) are dispersed in 1120 g of purified water. The suspension is sprayed onto 720 g of neutral microspheres (Asahi-Kasei) in a Glatt GPCG1 spray coater. - 43.2 g of hydrogenated cottonseed oil (Penwest) and 64.8 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 492 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles of example 5 and of comparative example 1 are presented in
FIG. 4 . It is noted that: -
- at pH 1.4, approximately 60% of the active principle is released after a lag period of approximately 1.5 hours;
- when the pH goes from 1.4 to 6.8, the release kinetics are rapid.
- 630 g of amoxicillin trihydrate, 90 g of povidone (plasdone® K29/32 (ISP)) and 180 g of crospovidone (Polyplasdone®/ISP) are dispersed in 2100 g of isopropanol/water mixture (70/30 m/m). The solution is sprayed onto 100 g of neutral microspheres (Asahi-Kasei) in a Glatt® GPCG1 spray coater.
- 120 g of hydrogenated cottonseed oil (Abitec) and 160 g of poly(methacrylic acid) (ethyl acrylate) Kollicoat® MAE 100P (BASF) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 700 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles of example 6 and of comparative example 2 are presented in
FIG. 6 . It is noted that with the composition according to the invention: -
- the release of the active principle at pH 1.4 was accelerated (guaranteeing triggering of the system after a given period of time and the release of a sufficient amount of active agent, this release taking place over time periods compatible with the absorption times of the active principles in the organism);
- when the pH goes from 1.4 to 6.8, rapid release kinetics are maintained.
- 400 g of nitrofurantoin, 200 g of povidone (plasdone® K29/32/ISP), 50 g of PEG-40 hydrogenated castor oil (BASF) and 350 g of crospovidone (Polyplasdone®/ISP) are suspended in 2500 g of purified water. The solution is sprayed onto 1000 g of neutral microspheres (Asahi-Kasei) in a Glatt® GPCG1 spray coater.
- 120 g of hydrogenated cottonseed oil (Abitec) and 160 g of poly(methacrylic acid) (ethyl acrylate) Acrycoat® L100D (NP Pharm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 700 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles of example 7 and of comparative example 3 are presented in
FIG. 7 . It is noted that, with the composition according to the invention: -
- the release of the active principle at pH 1.4 was accelerated (guaranteeing triggering of the system after a given period of time and the release of a sufficient amount of active agent, this release taking place over time periods compatible with the absorption times of the active principles in the organism);
- when the pH goes from 1.4 to 6.8, rapid release kinetics are maintained.
- 75 g of acyclovir and 75 g of povidone (Plasdone® K29/32/ISP) are dissolved in 833 g of isopropanol. The solution is sprayed onto 850 g of neutral microspheres (NP Pharm) in a Glatt® GPCG3 spray coater.
- 93.3 g of hydrogenated soybean oil (Abitec) and 140 g of poly(methacrylic acid) (methyl methacrylate) Eudragit® L100 (Röhm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 700 g of previously prepared microparticles.
- 375 g of acyclovir, 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 75 g of crospovidone (Polyplasdone®/ISP are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG3 spray coater.
- 100 g of hydrogenated cottonseed oil (Penwest) and 150 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) are dissolved under hot conditions in ethanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- 300 g of acyclovir, 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 150 g of crospovidone (Polyplasdone®/ISP are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG3 spray coater.
- 100 g of hydrogenated cottonseed oil (Penwest) and 150 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) are dissolved under hot conditions in ethanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step in comparative examples 8, 9 and 10 were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles of examples 8, 9 and 10 are presented in
FIGS. 8 and 9 . It is noted that: -
- a broad kinetics range can be obtained at pH 1.4 depending on the amount of swelling agent incorporated into the formulation;
- the release at pH 6.8 remains rapid regardless of the composition under consideration.
- 300 g of acyclovir, 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 150 g of sodium croscarmellose (Ac-Di-Sol®/FMC) are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG1 spray coater.
- 100 g of hydrogenated cottonseed oil (Penwest) and 100 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) are dissolved under hot conditions in ethanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- 300 g of acyclovir, 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 150 g of hydroxypropylmethylcellulose (Pharmacoat 615/Shin-Etsu) are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG1 spray coater.
- 100 g of hydrogenated cottonseed oil (Penwest), 100 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) and 50 g of poly(methacrylic acid) (methyl methacrylate) Eudragit® S100 (Röhm) are dissolved under hot conditions in ethanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- 350 g of acyclovir, 50 g of low molar mass hydroxypropylcellulose (Klucel® EF (Hercules)) and 100 g of high molar mass povidone (Kollidon® 90 (BASF)) are suspended in 1200 g of purified water. The solution is sprayed onto 500 g of neutral microspheres (NP Pharm) in a Glatt® GPCG1 spray coater.
- 100 g of hydrogenated cottonseed oil (Penwest), 50 g of poly(methacrylic acid) (ethyl acrylate) Eudragit® L100-55 (Röhm) and 100 g of poly(methacrylic acid) (methyl methacrylate) Eudragit® S100 (Röhm) are dissolved under hot conditions in ethanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step in examples 10, 11, 12 and 13 were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, at pH 1.4.
- The dissolution profiles are presented in
FIG. 10 . - 700 g of acyclovir, 50 g of povidone (Plasdone®/ISP) and 250 g of crospovidone (Polyplasdone®/ISP) are dry-mixed beforehand in a laboratory granulator (Lodige) for 5 minutes. This pulverulent mixture is then granulated with water (200 g). The granules are dried at 40° C. in a ventilated oven, and then calibrated on a 500 μm screen. The 200-500 μm fraction is selected by screening.
- 100 g of hydrogenated palm oil (Huls), 100 g of poly(methacrylic acid) (ethyl acrylate) Acrycoat L100D and 50 g of poly(methacrylic acid) (methyl methacrylate) Acrycoat® S100 (NP Pharm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step of example 13 were tested in a type II dissolutest in accordance with the European Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in
FIG. 11 . - 700 g of acyclovir, 50 g of povidone (Plasdone®/ISP) and 250 g of crospovidone (Kollidon® CL/BASF) are premixed with 150 g of water in a laboratory mixer (Kitchen-Aid) for 5 minutes. This pasty mixture is extruded through a 0.5 mm screen using an extruder 20 (Caleva). The filaments obtained are then spheronized using a spheronizer 250 (Caleva). The particles obtained are dried at 40° C. in a fluidized airbed. The 300-700 μm fraction is selected by screening.
- 100 g of hydrogenated palm oil (Huls), 100 g of poly(methacrylic acid) (ethyl acrylate) Acrycoat L100D and 50 g of poly(methacrylic acid) (methyl methacrylate) Acrycoat® S100 (NP Pharm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step of example 14 were tested in a type II dissolutest in accordance with the Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in
FIG. 12 . - 590 g of acyclovir, 10 g of magnesium stearate and 400 g of crospovidone are mixed using a laboratory mixer (Kitchen-Aid type) for 5 minutes. This mixture is then compacted using an Alexanderwerk WP120 laboratory compactor. The product obtained is then granulated using an Erweka oscillating granulator equipped with a 500 μm screen. The 100-500 μm fraction of the product obtained is selected by screening.
- 100 g of hydrogenated palm oil (Huls), 100 g of poly(methacrylic acid) (ethyl acrylate) Acrycoat L100D and 50 g of poly(methacrylic acid) (methyl methacrylate) Acrycoat® S100 (NP Pharm) are dissolved under hot conditions in isopropanol. The solution is sprayed onto 750 g of previously prepared microparticles.
- The microcapsules obtained at the end of the second step of example 14 were tested in a type II dissolutest in accordance with the Pharmacopoeia 4th edition, at 37° C. and with stirring at 100 rpm, in the following media:
-
- HCl at pH 1.4,
- HCl at pH 1.4 for 2 hours and then KH2PO4/NaOH buffer medium, at pH 6.8.
- The dissolution profiles are presented in
FIG. 13 . - Various microunits of acyclovir are prepared, in which microunits:
-
- 25% by weight of the acyclovir is in the form of immediate-release microunits as obtained at the end of the first step of example 12,
- 25% by weight of the acyclovir is in the form of delayed- and prolonged-release microunits as obtained at the end of the second step of example 10, and
- 50% by weight of the acyclovir is in the form of delayed- and prolonged-release microcapsules as obtained at the end of the second step of example 12.
- The microcapsules of example No. 10 begin to rapidly release their content above pH>5.5 (use of Eudragit® L100-55).
- The microcapsules of example No. 12 begin to rapidly release their content above pH>6.5 (use of 67% Eudragit® L100-55 and 33% Eudragit® S100).
- The profiles are presented in
FIG. 14 which show that various release phases are obtained, thereby optimizing the release of an active principle in front of its absorption window.
Claims (40)
1. An oral medicament comprising a plurality of microcapsules for the modified release of active principle(s), at least some of said microcapsules consisting individually of a microparticle comprising at least one active principle, in particular at least one low-solubility active principle (with the exclusion of carvedilol), coated with at least one coating for the modified release of the active principle(s), said release being controlled by two distinct trigger mechanisms, one being based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of time spent in the stomach,
said coating also conferring on the microcapsules an in vitro dissolution behavior such that:
at constant pH 1.4, the dissolution profile comprises a lag phase less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably between 1 and 5 hours, in duration;
the passing from pH 1.4 to pH 7.0 results in a release phase which begins without any lag time;
characterized
in that at least some of said microcapsules comprise at least one swelling agent,
and in that the fraction by weight of the active principle(s) released during the lag phase is less than or equal to 15% by weight per hour, preferably less than or equal to 10% by weight per hour, and even more preferably less than or equal to 5% by weight per hour.
2. The medicament as claimed in claim 1 , characterized in that the swelling agent comprises at least one hydrophilic pharmaceutically acceptable compound which exhibits a degree of swelling in water at 25° C. of greater than or equal to 10% by weight, preferably greater than or equal to 15% by weight, and even more preferably greater than or equal to 20%.
3. The medicament as claimed in claim 1 , characterized in that the swelling agent is chosen from those which allow the microcapsules to release at least 50% by weight of the active principle, after 16 h at pH 1.4, in an in vitro dissolution test.
4. The medicament as claimed in claim 2 , characterized in that the swelling agent is in the form of microparticles which have an average diameter of between 5 and 200 μm, and preferably between 10 and 50 μm.
5. The medicament as claimed in claim 2 , characterized in that the concentration (Cd) of swelling agent is defined as follows (in % by weight relative to the total mass of the microcapsules):
3≦Cd≦40,
preferably, 4≦Cd≦30,
and even more preferably, 5≦Cd≦25.
6. The medicament as claimed in claim 2 or 3 , characterized in that the swelling agent is chosen from the group of following products:
crosslinked polyvinylpyrrolidones (e.g. polyplasdone or crospovidone),
crosslinked carboxyalkylcelluloses: crosslinked carboxymethylcelluloses (e.g. crosslinked sodium croscarmellose),
and also high molar mass hydrophilic polymers (greater than or equal to 100 000 D) such as:
polyvinylpyrrolidones,
polyalkylene oxides (e.g. polyethylene oxide or polypropylene oxide),
(hydroxy)(alkyl)celluloses (e.g. hydroxypropylcellulose, hydroxypropylmethylcellulose),
carboxyalkylcelluloses (e.g. carboxymethyl-cellulose),
celluloses (powder or microcrystalline),
modified starches (for example modified with sodium glycolate),
natural starches (for example from maize, wheat or potato),
sodium alginate,
potassium polacriline,
and mixtures thereof.
7. The medicament as claimed in one of the preceding claims, characterized in that it comprises at least one wetting agent, preferably chosen from the group of following products:
anionic surfactants, preferably in the subgroup of alkali metal or alkaline earth metal salts of fatty acids, stearic acid and/or oleic acid being preferred,
and/or nonionic surfactants, preferably in the following subgroup:
polyoxyethylenated oils, preferably polyoxyethylenated hydrogenated castor oil,
polyoxyethylene-polyoxypropylene copolymers,
polyoxyethylenated sorbitan esters,
polyoxyethylenated castor oil derivatives,
stearates, preferably calcium stearate, magnesium stearate, aluminum stearate or zinc stearate,
stearyl fumarates, preferably sodium stearyl fumarate,
glyceryl behenate,
and mixtures thereof.
8. The medicament as claimed in one of the preceding claims, characterized in that the swelling agent and/or the wetting agent is contained in the microparticle of active principle.
9. The medicament as claimed in one of the preceding claims, characterized in that the microcapsules of active principle(s) that it comprises are capable of releasing at least 80% by weight of the active principle(s), after 12 h at pH=7.0, in an in vitro dissolution test.
10. The medicament as claimed in one of the preceding claims, characterized in that at least some of the microcapsules for the modified release of active principle(s) each comprise:
a microparticle of active principle(s), coated with
at least one coating for the modified release of the active principle(s).
11. The medicament as claimed in one of the preceding claims, characterized in that at least some of said microcapsules for the modified release of active principle comprise:
a neutral core,
at least one active layer comprising the active principle(s) and coating the neutral core, and
at least one coating for the modified release of the active principle.
12. The medicament as claimed in one of the preceding claims, characterized in that:
the coating for the modified release of the active principle(s) comprises a composite material
comprising:
at least one hydrophilic polymer A bearing groups that are ionized at neutral pH,
at least one hydrophobic compound B,
representing a mass fraction (% weight relative to
the total mass of the microcapsules)≦40; and
the microcapsules have an average diameter of less than 2000 μm.
13. The medicament as claimed in claim 12 , characterized in that the composite material AB of the coating for the modified release of the low-solubility active principle is such that:
the weight ratio B/A is between 0.2 and 1.5, preferably between 0.5 and 1.0,
and the hydrophobic compound B is selected from products that are crystalline in the solid state and have a melting point MpB≧40° C., preferably MpB≧50° C., and even more preferably 40° C.≦MpB≦90° C.
14. The medicament as claimed in either of claims 12 and 13 , characterized in that the hydrophilic polymer A is chosen from:
A.a copolymers of (meth)acrylic acid and of a (meth)acrylic acid alkyl ester, and mixtures thereof;
A.b cellulose derivatives, preferably cellulose acetates, cellulose phthalates, cellulose succinates and mixtures thereof, and even more preferably hydroxypropylmethylcellulose phthalates, hydroxypropylmethylcellulose acetates, hydroxypropylmethylcellulose succinates and mixtures thereof;
and mixtures thereof.
15. The medicament as claimed in one of claims 12 to 14, characterized in that the compound B is chosen from the group of following products:
B.a plant waxes taken on their own or as mixtures with one another;
B.b hydrogenated plant oils taken on their own or as mixtures with one another;
B.c mono- and/or di- and/or triesters of glycerol and of at least one fatty acid;
B.d mixtures of monoesters, of diesters and of triesters of glycerol and of at least one fatty acid;
B.e and mixtures thereof.
16. The medicament as claimed in claim 15 , characterized in that the compound B is chosen from the group of following products:
hydrogenated cottonseed oil, hydrogenated soya bean oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin, yellow wax, hard fat or fat that can be used as bases for suppositories, anhydrous dairy fats, lanolin, glyceryl palmitostearate, glyceryl stearate, lauryl macrogolglycerides, cetyl alcohol, polyglyceryl diisostearate, diethylene glycol monostearate, ethylene glycol monostearate, Omega 3 and any mixture thereof,
preferably from the subgroup of following products: hydrogenated cottonseed oil, hydrogenated soya bean oil, hydrogenated palm oil, glyceryl behenate, hydrogenated castor oil, tristearin, tripalmitin, trimyristin, and any mixture thereof.
17. The medicament as claimed in claim 16 , characterized in that the compound B is chosen:
from the group of products sold under the following trademarks: Dynasan®, Cutina®, Hydrobase®, Dub®, Castorwax®, Croduret®, Compritol®, Sterotex®, Lubritab®, Apifil®, Akofine®, Softtisan®, Hydrocote®, Livopol®, Super Hartolan®, MGLA®, Corona®, Protalan®, Akosoft®, Akosol®, Cremao®, Massupol®, Novata®, Suppocire®, Wecobee®, Witepsol®, Lanolin®, Incromega®, Estaram®, Suppoweiss®, Gelucire®, Precirol®, Emulcire®, Plurol diisostearique®, Geleol®, Hydrine® and Monthyle® and mixtures thereof;
and also from the group of additives for which the codes are the following: E 901, E 907, E 903 and mixtures thereof;
and, preferably from the group of commercial products sold under the following trademarks: Dynasan® P60, Dynasan® 114, Dynasan® 116, Dynasan® 118, Cutina® HR, Hydrobase® 66-68, Dub® HPH, Compritol® 888, Sterotex® NF, Sterotex® K, Lubritab® and mixtures thereof.
18. The medicament as claimed in any one of claims 12 to 17, characterized in that the coating of the microcapsules for the modified release of active principle comprises a single coating film comprising the composite AB.
19. An oral medicament comprising a plurality of microcapsules for the modified release of active principle(s), at least some of said microcapsules consisting individually of a microparticle comprising at least one active principle, in particular at least one low-solubility active principle (with the exclusion of carvedilol), coated with at least one coating for the modified release of the active principle(s), said release being controlled by two distinct trigger mechanisms, one based on a variation in pH and the other allowing the release of the active principle(s) after a predetermined period of time spent in the stomach,
said coating:
also conferring on the microcapsules an in vitro dissolution behavior such that:
at constant pH 1.4, the dissolution profile comprises a lag phase of less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably between 1 and 5 hours, in duration;
the passing from pH 1.4 to pH 7.0 results in a release phase which begins without any lag time;
and comprising a composite material comprising at least one hydrophilic polymer A bearing groups that are ionized at neutral pH and at least one hydrophobic compound B;
characterized in that at least some of said microcapsules comprise at least one release helper capable of increasing the permeability of the coating for the modified release of the active principle(s), and in that the fraction by weight of the active principle(s) released during the lag phase is less than or equal to 15% by weight per hour, preferably less than or equal to 10% by weight per hour, and even more preferably less than or equal to 5% by weight per hour.
20. The medicament as claimed in claim 19 , characterized in that the release helper consists of at least one swelling agent.
21. The medicament as claimed in claim 19 or 20 , characterized in that the coating of the microcapsules confers on them an in vitro dissolution behavior such that at least 50% by weight of the active principle(s) is released after 16 h at pH 1.4.
22. The medicament as claimed in one of claims 1 to 20, characterized in that it comprises a mixture of various populations of microunits containing active principle(s), with the exclusion of carvedilol, these populations differing from one another by virtue of their respective in vitro dissolution profiles, for at least one pH value of between 1.4 and 7.4.
23. The medicament as claimed in claim 21 and at least one of the other preceding claims, characterized in that the microunits are microcapsules for the modified release of active principle(s) and, optionally, microunits for the immediate release of active principle(s).
24. The medicament as claimed in claim 22 , characterized in that the populations of microcapsules for the modified release of active principle differ by virtue of their respective trigger pHs.
25. The medicament as claimed in claim 22 , characterized in that the populations of microcapsules for the modified release of active principle differ by virtue of their respective trigger times.
26. The medicament as claimed in claim 22 , characterized in that it comprises:
i. at least one population of microunits containing immediate-release active principle;
ii. at least one population P1 of microcapsules for the modified release of active principle(s), and
iii. at least one population P2 of microcapsules for the modified release of active principle(s);
and in that the respective trigger pHs of P1 and of P2 differ by at least 0.5 pH unit, preferably by at least 0.8 pH unit, and even more preferably by at least 0.9 pH unit.
27. The medicament as claimed in claim 22 , characterized in that the respective trigger pHs of the various populations of microcapsules for the modified release of active principle(s) are between 5 and 7.
28. The medicament as claimed in claim 22 , characterized in that it comprises:
i. at least one population of microunits containing immediate-release active principle(s),
ii. at least one population P1′ of microunits containing active principle(s) made up of microcapsules for the modified release of the active principle(s), the trigger pH of which is equal to 5.5, and
iii. at least one population P2′ of microunits containing active principle(s) made up of microcapsules for the modified release of the active principle(s), the trigger pH of which is equal to 6.0 or 6.5.
29. The medicament as claimed in one of claims 22 to 28, characterized in that the release profile, measured in an in vitro release test, is as indicated hereinafter:
less than 20% of the active principle(s) is released after 2 hours at pH=1.4;
at least 50% of the active principle(s) is released after 16 hours at pH=1.4.
30. The medicament as claimed in one of claims 22 to 29, characterized in that it comprises at least one population of microunits containing immediate-release active principle(s), the behavior of which in an in vitro dissolution test is such that at least 80% of the active principle(s) is released in 1 hour at any pH between 1.4 and 7.4.
31. The medicament as claimed in one of claims 22 to 30, characterized in that the proportion of low-solubility active principle(s) in the microunits containing active principle(s) (expressed as % by weight on a dry weight basis, relative to the total mass of the microunits) is between 5 and 80, preferably between 10 and 70, and even more preferably between 15 and 60.
32. The medicament as claimed in one of claims 22 to 31, characterized in that the microunits containing immediate-release active principle(s) are uncoated microparticles.
33. The medicament as claimed in one of the preceding claims, characterized in that it is in the form of a single daily oral dose comprising from 5000 to 500 000 microunits containing active principle(s).
34. The medicament as claimed in one of the preceding claims, characterized in that it is in the form of a single daily oral dose comprising from 5000 to 500 000 microcapsules for the modified release of active principle(s).
35. The medicament as claimed in one of the preceding claims, characterized in that it is in the form of a sachet of microcapsule powder, of a liquid suspension of microcapsules, of a tablet obtained from microcapsules, or of a gelatin capsule containing microcapsules.
36. The medicament as claimed in one of the preceding claims, characterized in that the active principle(s) can be chosen from at least one of the following main varieties of active substances, e.g.: antiulcer agents, antidiabetic agents, anticoagulants, antithrombotics, blood-lipid-lowering agents, antiarrhythmics, vasodilators, anti-angina agents, antihypertensives, vasoprotectors, fertility promoters, inhibitors and inducers of uterine labor, contraceptives, antibiotics, antifungals, antivirals, anticancer agents, anti-inflammatories, analgesics, antiepileptics, anti-parkinsonian agents, neuroleptics, hypnotics, anxiolytics, psychostimulants, antimigraine agents, antidepressants, antitussives, antihistamines or anti-allergic agents, agents for combating congestive heart failure, angina pectoris, left ventricular hypertrophy, cardiac arrhythmias, myocardial infarction, reflex tachycardia, ischemic heart disease, atheromatosis, diabetes mellitus-related hypertension, portal hypertension, vertigo, abradycardia, arterial hypotension, water and sodium retention, acute renal insufficiency, orthostatic hypotension and cerebral congestion, and mixtures thereof.
37. The medicament as claimed in one of the preceding claims, characterized in that the active principle(s) is (are) chosen from the group of products comprising: acetylsalicylic acid, carbamazepine pentoxifylline, prazosine, acyclovir, nifedipine, diltiazem, naproxen, ibuprofen, flurbiprofen, ketoprofen, fenoprofen, indomethacin, diclofenac, fentiazac, estradiol valerate, metoprolol, sulpiride, captopril, cimetidine, zidovudine, nicardipine, terfenadine, atenolol, salbutamol, carbamazepine, ranitidine, enalapril, simvastatin, fluoxetine, alprazolam, famotidine, ganciclovir, famciclovir, spironolactone, 5-asa, quinidine, perindopril, morphine, pentazocine, paracetamol, omeprazole, lansoprazole, metoclopramide, aminosalicylic acid, nalidixic acid, amoxicillin, amoxicillin and potassium clavulanate, ampicillin, ampicillin and sulbactam, azithromycin, bacampicillin, carbenicillin-indanyl-sodium (and other carbenicillin salts), capreomycin, cefadroxil, cefazoline, cephalexine, cephalothine, cephapirine, cephacelor, cephprozile, cephadrine, cefamandole, cefonicide, ceforanide, cefuroxime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftaxidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, cefinetazole, cefotetan, cefoxitin, ciprofloxacin, clarithromycin, clindamycin, clofazimine, cloxacillin, cotriamoxazole, cycloserine, dicloxacillin, dirithromycin, erythromycin (and erythromycin salts such as estolate, ethyl succinate, gluceptate, lactobionate, stearate), ethambutol-HCl and other salts, ethionamide, fosfomycin, imipenem, isoniazide, levofloxacin, lomefloxacin, loracarbef, methicillin, methenamine, metronidazole, metoclopramide, mezlocillin, nafcillin, nitrofurantoin, norfloxacine, novobiocine, ofloxacine, oxacillin, penicillin V, penicillin salts, penicillin complexes, pentamidine, piperacillin, piperacillin and tazobactam, sparfloxacine, sulfacytine, sulfamerazine, sulfamethazine, sulfamethixole, sulfasalazine, sulfisoxazole, sulfapyrizine, sulfadiazine, sulfinethoxazole, sulfapyridine, ticarcillin, ticarcillin and potassium clavulanate, trimethoprim, trimetrexate, troleanomycin, vancomycin, verapamil and mixtures thereof.
38. The medicament as claimed in one of the preceding claims, characterized in that the active principle(s) is (are) a low-solubility active principle or low-solubility active principles.
39. The use of the microcapsules for the modified release of active principle(s) (with the exclusion of carvedilol) as defined in any one of claims 1 to 38 and, optionally, of the microunits containing immediate-release active principle, for the preparation of pharmaceutical or dietetic, microparticulate oral galenic forms, preferably in the form of advantageously orodispersible tablets, of powders or of gelatin capsules.
40. The microcapsule as defined in any one of the preceding claims.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0452748 | 2004-11-24 | ||
FR0452748A FR2878159B1 (en) | 2004-11-24 | 2004-11-24 | ORAL MEDICATION WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE IN MULTIMICROCAPSULAR FORM |
PCT/FR2005/050922 WO2006056711A2 (en) | 2004-11-24 | 2005-11-02 | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080305160A1 true US20080305160A1 (en) | 2008-12-11 |
Family
ID=34953830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/791,466 Abandoned US20080305160A1 (en) | 2004-11-24 | 2005-11-02 | Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule Form |
Country Status (18)
Country | Link |
---|---|
US (1) | US20080305160A1 (en) |
EP (1) | EP1827396B1 (en) |
JP (1) | JP5619342B2 (en) |
KR (1) | KR101391287B1 (en) |
CN (1) | CN101094658B (en) |
AU (1) | AU2005308639B2 (en) |
BR (1) | BRPI0518266B8 (en) |
CA (1) | CA2589137C (en) |
ES (1) | ES2588160T3 (en) |
FR (1) | FR2878159B1 (en) |
HU (1) | HUE029440T2 (en) |
IL (1) | IL183357A (en) |
MX (1) | MX2007006212A (en) |
PT (1) | PT1827396T (en) |
SG (1) | SG157406A1 (en) |
TW (1) | TW200630123A (en) |
WO (1) | WO2006056711A2 (en) |
ZA (1) | ZA200704163B (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20100273747A1 (en) * | 2009-04-22 | 2010-10-28 | Dr. Suwelack Skin & Health Care Ag | Freeze-Dried Composition of Active Substances |
US20110038931A1 (en) * | 2008-02-22 | 2011-02-17 | Hanall Biopharma Co., Ltd. | Composite preparation |
US20110052683A1 (en) * | 2008-02-22 | 2011-03-03 | Hanall Biopharma Co., Ltd. | Pharmaceutical preparation for treating cardiovascular disease |
WO2013151518A1 (en) * | 2012-04-04 | 2013-10-10 | Mahmut Bilgic | Capsule formulations comprising ceftibuten |
US8580302B2 (en) | 2000-11-20 | 2013-11-12 | Warner Chilcott Company, Llc | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10624899B2 (en) | 2016-07-14 | 2020-04-21 | Achaogen, Inc. | Combination products for the treatment of bacterial infections and methods of producing or dosing of same |
EP3137060B1 (en) | 2014-05-01 | 2020-11-11 | Sun Pharmaceutical Industries Ltd | Extended release suspension compositions |
US11077055B2 (en) | 2015-04-29 | 2021-08-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
GB202116590D0 (en) | 2021-11-17 | 2021-12-29 | Rb Health Us Llc | Novel composition |
GB202116589D0 (en) | 2021-11-17 | 2021-12-29 | Rb Health Us Llc | Novel composition |
GB202116588D0 (en) | 2021-11-17 | 2021-12-29 | Rb Health Us Llc | Novel composition |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100310475A1 (en) * | 2007-06-18 | 2010-12-09 | Dolhay Klinika Egeszsegugyi Kft. | Biocide Capsules, Preparation Comprising them and Sanitary Pad Comprising the Preparation |
US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
VN27088A1 (en) * | 2008-07-31 | 2011-08-25 | Feyecon Bv | Microencapsulate and process for the manufacture thereof. |
SG186301A1 (en) * | 2010-06-16 | 2013-02-28 | Takeda Pharmaceuticals Usa Inc | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
CN101912403B (en) * | 2010-08-02 | 2012-01-11 | 陶灵刚 | Cefoperazone sodium and tazobactam sodium medicinal composition microsphere injection |
CN105560212B (en) * | 2016-03-24 | 2018-11-02 | 长沙佰顺生物科技有限公司 | A kind of preparation method of captopril micro-capsule |
UY37341A (en) * | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
CN108558690B (en) * | 2018-03-28 | 2021-04-20 | 浙江海正药业股份有限公司 | Crystal form of cycloserine esterified substance hydrochloride and preparation method thereof |
JP2022522270A (en) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | Gamma-hydroxybutyrate composition with improved pharmacokinetics in dietary intake |
KR102546722B1 (en) * | 2020-04-21 | 2023-06-23 | 주식회사 바이오스탠다드 | Cosmetic composition for skin condition improving containing biocopolymer micro capsule, and method for manufacturing the same |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4833905A (en) * | 1983-06-03 | 1989-05-30 | Micromatic Textron Inc. | Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness |
US4884905A (en) * | 1987-01-09 | 1989-12-05 | International Business Machines Corporation | Print head incorporating one piece armature with intermediate clamping pads |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US6022562A (en) * | 1994-10-18 | 2000-02-08 | Flamel Technologies | Medicinal and/or nutritional microcapsules for oral administration |
US20020110593A1 (en) * | 1999-06-04 | 2002-08-15 | Adel Penhasi | Delayed total release two pulse gastrointestinal drug delivery system |
US20020122822A1 (en) * | 2000-12-29 | 2002-09-05 | Bunick Frank J. | Process for preparing a soft tablet |
US20040234601A1 (en) * | 2001-10-09 | 2004-11-25 | Valerie Legrand | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20050037077A1 (en) * | 2001-10-09 | 2005-02-17 | Valerie Legrand | Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62195323A (en) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | Gastric resident particle |
AU4800999A (en) * | 1998-07-28 | 2000-02-21 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
JP2000103732A (en) * | 1998-07-28 | 2000-04-11 | Tanabe Seiyaku Co Ltd | Intestinal right place release preparation |
JP4578124B2 (en) * | 2003-03-12 | 2010-11-10 | 武田薬品工業株式会社 | A pharmaceutical composition in which an active ingredient is attached to a spherical nucleus at a high concentration |
CA2532310A1 (en) * | 2003-07-17 | 2005-02-03 | Dr. Reddy's Laboratories, Inc. | Pharmaceutical compositions having a swellable coating |
-
2004
- 2004-11-24 FR FR0452748A patent/FR2878159B1/en active Active
-
2005
- 2005-10-25 TW TW094137320A patent/TW200630123A/en unknown
- 2005-11-02 ES ES05819012.5T patent/ES2588160T3/en active Active
- 2005-11-02 KR KR1020077014469A patent/KR101391287B1/en not_active IP Right Cessation
- 2005-11-02 EP EP05819012.5A patent/EP1827396B1/en active Active
- 2005-11-02 CN CN200580045905.XA patent/CN101094658B/en active Active
- 2005-11-02 BR BRPI0518266A patent/BRPI0518266B8/en active IP Right Grant
- 2005-11-02 AU AU2005308639A patent/AU2005308639B2/en active Active
- 2005-11-02 JP JP2007542057A patent/JP5619342B2/en active Active
- 2005-11-02 WO PCT/FR2005/050922 patent/WO2006056711A2/en active Application Filing
- 2005-11-02 US US11/791,466 patent/US20080305160A1/en not_active Abandoned
- 2005-11-02 PT PT58190125T patent/PT1827396T/en unknown
- 2005-11-02 CA CA2589137A patent/CA2589137C/en active Active
- 2005-11-02 SG SG200907745-4A patent/SG157406A1/en unknown
- 2005-11-02 MX MX2007006212A patent/MX2007006212A/en active IP Right Grant
- 2005-11-02 HU HUE05819012A patent/HUE029440T2/en unknown
-
2007
- 2007-05-21 ZA ZA200704163A patent/ZA200704163B/en unknown
- 2007-05-21 IL IL183357A patent/IL183357A/en not_active IP Right Cessation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4833905A (en) * | 1983-06-03 | 1989-05-30 | Micromatic Textron Inc. | Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness |
US4884905A (en) * | 1987-01-09 | 1989-12-05 | International Business Machines Corporation | Print head incorporating one piece armature with intermediate clamping pads |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US6022562A (en) * | 1994-10-18 | 2000-02-08 | Flamel Technologies | Medicinal and/or nutritional microcapsules for oral administration |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US20020110593A1 (en) * | 1999-06-04 | 2002-08-15 | Adel Penhasi | Delayed total release two pulse gastrointestinal drug delivery system |
US20020122822A1 (en) * | 2000-12-29 | 2002-09-05 | Bunick Frank J. | Process for preparing a soft tablet |
US20040234601A1 (en) * | 2001-10-09 | 2004-11-25 | Valerie Legrand | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20050037077A1 (en) * | 2001-10-09 | 2005-02-17 | Valerie Legrand | Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9089492B2 (en) | 2000-11-20 | 2015-07-28 | Warner Chilcott Company, Llc | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US8580302B2 (en) | 2000-11-20 | 2013-11-12 | Warner Chilcott Company, Llc | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20110052683A1 (en) * | 2008-02-22 | 2011-03-03 | Hanall Biopharma Co., Ltd. | Pharmaceutical preparation for treating cardiovascular disease |
US20110038931A1 (en) * | 2008-02-22 | 2011-02-17 | Hanall Biopharma Co., Ltd. | Composite preparation |
US9023369B2 (en) | 2009-04-22 | 2015-05-05 | Ralf Malessa | Freeze-dried composition of active substances |
US20100273747A1 (en) * | 2009-04-22 | 2010-10-28 | Dr. Suwelack Skin & Health Care Ag | Freeze-Dried Composition of Active Substances |
WO2013151518A1 (en) * | 2012-04-04 | 2013-10-10 | Mahmut Bilgic | Capsule formulations comprising ceftibuten |
EP3137060B1 (en) | 2014-05-01 | 2020-11-11 | Sun Pharmaceutical Industries Ltd | Extended release suspension compositions |
US11077055B2 (en) | 2015-04-29 | 2021-08-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10835488B2 (en) | 2016-06-16 | 2020-11-17 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10624899B2 (en) | 2016-07-14 | 2020-04-21 | Achaogen, Inc. | Combination products for the treatment of bacterial infections and methods of producing or dosing of same |
GB202116590D0 (en) | 2021-11-17 | 2021-12-29 | Rb Health Us Llc | Novel composition |
GB202116589D0 (en) | 2021-11-17 | 2021-12-29 | Rb Health Us Llc | Novel composition |
GB202116588D0 (en) | 2021-11-17 | 2021-12-29 | Rb Health Us Llc | Novel composition |
Also Published As
Publication number | Publication date |
---|---|
WO2006056711A2 (en) | 2006-06-01 |
KR101391287B1 (en) | 2014-05-19 |
IL183357A (en) | 2014-12-31 |
AU2005308639A1 (en) | 2006-06-01 |
TW200630123A (en) | 2006-09-01 |
CA2589137A1 (en) | 2006-06-01 |
FR2878159B1 (en) | 2008-10-17 |
WO2006056711A3 (en) | 2006-08-31 |
CN101094658A (en) | 2007-12-26 |
SG157406A1 (en) | 2009-12-29 |
ZA200704163B (en) | 2008-08-27 |
JP2008520633A (en) | 2008-06-19 |
HUE029440T2 (en) | 2017-02-28 |
BRPI0518266B1 (en) | 2020-07-07 |
EP1827396A2 (en) | 2007-09-05 |
MX2007006212A (en) | 2007-07-09 |
PT1827396T (en) | 2016-08-31 |
CN101094658B (en) | 2016-10-05 |
CA2589137C (en) | 2014-08-26 |
ES2588160T3 (en) | 2016-10-31 |
FR2878159A1 (en) | 2006-05-26 |
BRPI0518266A2 (en) | 2008-11-11 |
AU2005308639B2 (en) | 2011-05-26 |
BRPI0518266B8 (en) | 2021-05-25 |
KR20070098823A (en) | 2007-10-05 |
JP5619342B2 (en) | 2014-11-05 |
IL183357A0 (en) | 2007-09-20 |
BRPI0518266A8 (en) | 2016-03-29 |
EP1827396B1 (en) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE47084E1 (en) | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form | |
AU2005308639B2 (en) | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form | |
US8101209B2 (en) | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | |
JP4718116B2 (en) | Microparticulate oral galenical dosage form for delayed and controlled release of pharmaceutically active ingredients | |
US8007827B2 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties | |
US20110159088A1 (en) | ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS | |
JP4723243B2 (en) | Microcapsules for delayed and controlled release of perindopril | |
JP2009514784A (en) | Oral ribavirin pharmaceutical composition | |
US20090311315A1 (en) | Multimicroparticulate Oral Pharmaceutical Form with Modified Release of Angiotensin II Receptor Antagonists | |
US20090123536A1 (en) | Oral Pharmaceutical Form of Losartan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FLAMEL TECHNOLOGIES, S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GUIMBERTEAU, FLORENCE;CASTAN, CATHERINE;MEYRUEIX, REMI;REEL/FRAME:020311/0712;SIGNING DATES FROM 20070611 TO 20070619 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |